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Abstract
A new class of GABA reuptake inhibitors with sterically demanding, highly rigid tricyclic cage structures as the lipophilic
domain was synthesized and investigated in regard to their biological activity at the murine GABA transporters
(mGAT1–mGAT4). The construction of these compounds, consisting of nipecotic acid, a symmetric tricyclic amine, and a
plain hydrocarbon linker connecting the two subunits via their amino nitrogens, was accomplished via reductive amination
of a nipecotic acid derivative with an N-alkyl substituent displaying a terminal aldehyde function with tricyclic secondary
amines. The target compounds varied with regard to spacer length, the bridge size of one of the bridges, and the substituents
of the tricyclic skeleton to study the impact of these changes on their potency. Among the tested compounds nipecotic acid
ethyl ester derivates with phenyl residues attached to the cage subunit showed reasonable inhibitory potency and subtype
selectivity in favor of mGAT3 and mGAT4, respectively.
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Introduction
A balanced interplay between excitatory and inhibitory
neurotransmission represents the fundamental basis for
proper functioning of the central nervous system (CNS) in
mammals. A disruption of this interplay due to, for exam-
ple, an insufficient signaling of GABAergic neurons can
lead to or intensify neurological disorders like Alzheimer’s
disease (AD) [1, 2], depression [3], epilepsy [4, 5], or
Parkinson’s disease (PD) [6–8]. One approach to influence
the GABAergic neurotransmission and thus to treat the
aforementioned diseases is to increase the release and the
concentration of γ-aminobutyric acid 1 (GABA),
representing the predominant inhibitory neurotransmitter in
the CNS [9–11], in the synaptic cleft. As GABA is quickly
removed from the synaptic cleft by reuptake into the pre-
synaptic neurons and surrounding glia cells this may be
achieved by inhibition of the GABA transporters (GATs) in
charge of this process [12–14].
GATs are membrane-bound transport proteins of the
solute carrier family 6. They consist of 12 transmembrane
helices and translocate their substrate GABA through the
cell membrane by cotransport of sodium and chloride ions
[15, 16]. Latest findings suggest a stoichiometry of 3:1:1
(Na+:Cl−:GABA) for sodium and chloride ions and GABA
in this transport process [17]. For the GATs four different
subtypes are known, which are denominated differently
depending on the species they were cloned from [14, 18].
When originating from mouse tissue they are termed
mGAT1–mGAT4 [18–20]. For all other species including
human, dog, or rat they are denominated as GAT-1 (≡
mGAT1), BGT-1 (≡ mGAT2), GAT-2 (≡ mGAT3), and
GAT-3 (≡ mGAT4) whereby the individual transporter
name is provided with a prefix such as h for human to
indicate the individual species. This nomenclature has also
been adopted by the Gene Nomenclature Committee of the
Human Genome Organization (HUGO) but without any
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prefix as which it has also found use as a species inde-
pendent nomenclature system [18, 20, 21]. As the biological
test system applied in this study is based on GATs origi-
nating from mice, for the sake of consistency the corre-
sponding nomenclature mGAT1–mGAT4 will be used
throughout this paper.
Although they are structurally closely related,
mGAT1–mGAT4 are expressed very differently. The pre-
dominating transporter subtype in the CNS is mGAT1,
which is primarily located on the plasma membrane of
presynaptic GABAergic neurons [14, 18, 22]. mGAT4
represents the second most abundant GAT in the brain,
albeit with distinctly lower concentration than mGAT1,
where it is responsible for the transport of GABA into
glia cells which are neighboring the GABAergic neurons
[21–24]. In contrast mGAT2 and mGAT3 are only weakly
expressed in the brain and occur mainly in kidney and liver.
As the level of mGAT2 and mGAT3 in the brain is too low
for having a reasonable effect on the termination of
GABAergic neurotransmission, mGAT1 and mGAT4 are
the most promising targets amongst these proteins to be
addressed for the treatment of above-mentioned diseases
[22, 25, 26].
Muscimol (2) and THPO (3) which are structurally
related to GABA (Fig. 1), the natural substrate of GATs,
were identified to be weak inhibitors at GATs. Structural
alterations of the isoxazolol function of THPO (3) led to
racemic nipecotic acid (rac-4) and guvacine (5) as the first
reasonably potent inhibitors of the GATs. However,
because of their zwitterionic character at physiological pH
and their high polarity these compounds are not able to pass
the blood–brain barrier (BBB). In order to increase lipo-
philicity and BBB permeation di- and triaryl residues were
added via a linker to the amino nitrogen of the parent
compounds. GAT inhibitors of this general structure have
been synthesized in large numbers and broad structural
diversity [27–33]. This includes the most prominent GAT
inhibitor Tiagabine 6, a mGAT1 selective inhibitor, which
is used in the treatment of epileptic seizures [34, 35]. The N-
linked lipophilic aryl-alkyl side chain does not only
improve the permeation of the BBB but often also mediates
a substantial increase in potency and subtype selectivity of
the GAT inhibitors. Modeling studies revealed the putative
binding pose for mGAT1 inhibitors such as Tiagabine (6).
According to that the amino acid subunit binds in the
substrate-binding pocket (S1) whereas the lipophilic residue
is accommodated in a binding site (S2) equipped with ali-
phatic residues and located in the vestibule oriented towards
the extracellular space [36–38]. NO711 (7) and (S)-SNAP-
5114 (8) represent two further well known GAT inhibitors
(Fig. 2) of which the former, 7, like Tiagabine (6) is highly
selective for mGAT1 and can be considered like 6 as pro-
totype for compounds exhibiting this subtype selectivity. A
major difference of (S)-SNAP-5114 (8) as compared to
these compounds is to be attributed to the lipophilic
domain, which by comprising a triarylmethyl unit is dis-
tinctly larger than that of 6 and 7. It is this large steric
demand of the lipophilic triarylmethyl subunit together with
the (S)-configuration of nipecotic acid that is thought to
mediate the subtype selectivity for mGAT4 of (S)-SNAP-
5114 (8) [16, 39].
Tiagabine (6) suffers from a series of adverse side effects
and (S)-SNAP-5114 (8), though among the most potent
mGAT4 inhibitors, of moderate potency [39, 40]. Thus
there is still a great need for GAT inhibitors with less
adverse effects and higher potency. Structural changes to
the aforementioned prototypic structures led to compounds
with partially rigidized lipophilic domains at the terminal
position of alkyl or heteroalkyl chains originating from the
amino nitrogen of the polar subunit [41, 42]. That way aryl
groups present in the lipophilic domain were forced to adopt
specific spatial orientations. Another option to achieve a
well-defined orientation of substituents in the lipophilic
domain is to use compounds with a polycyclic cage struc-
ture as central unit. The high rigidity of cage structures
allows to reduce the flexibility of attached substituents and
may lower the conformational entropy penalty resulting
from target binding [43, 44]. In addition, the high lipophi-
licity of cage-derived hydrocarbon rich structures may
positively affect the pharmacokinetic and pharmacody-
namic properties of drugs as it can facilitate the crossing of
the BBB and the binding to lipophilic domains [45, 46]. As
a result of their inherent stability and steric bulk, polycyclic
cage compounds also can slow down metabolic degradation
[45–47]. Currently drugs with polycyclic cage structures are









Fig. 1 Structures of GABA and some low molecular weight GAT inhibitors
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AD and PD [46]. The drug Deramciclane (rac-9) is a rare
example for a GAT inhibitor albeit with moderate inhibitory
activity at all four GAT subtypes in which a polycyclic cage
serving as lipophilic residue is present [48]. Since no sys-
tematic study aiming at the development of GAT inhibitors
with a polycyclic cage subunit as lipophilic domain has
been presented so far, though this appears to be quite
rewarding, we intended to carry out such a study.
To this end, polycyclic cage structures based on a 2-
azabicyclo[2.2.2]octane scaffold should be used, as they are
easily available by an efficient and straightforward synthesis
recently reported by us [49, 50]. For the present study the
symmetric tricyclic imines 10 should be used (for general
structure see Fig. 3). Though these polycyclic imines 10
display the same 2-azabicyclo[2.2.2]octane skeleton, the
size of the bridge between the two substituted bridgehead
atoms and thus the size of the tricyclic scaffold but also the
orientation of the bridgehead substituents may be varied
[51], thus allowing to study the impact of these two
parameters on the inhibitory potency of the target com-
pounds. As bridgehead substituents initially exclusively
methyl and phenyl residues should be used as the synthesis
of the respective symmetric tricyclic imines is known [51].
For the connection of these tricyclic cage units via their
amino nitrogen, resulting from reduction of the imine
function, with the amino nitrogen of racemic nipecotic acid
(rac-4) a plain alky chain linker of varying length should be
used. That way, the influence of the linker length on the
biological activity should be explored as well.
Materials and methods
Anhydrous reactions were performed under an argon
atmosphere in vacuum-dried glassware. All solvents were
distilled prior to use and dry 1,4-dioxane and CH2Cl2 were
prepared under a nitrogen atmosphere according to standard
procedures [52]. The CH2Cl2 employed as solvent in reac-
tions was stabilized with amylene, the CH2Cl2 used for
workups was stabilized with ethanol. All purchased che-
micals were used without further purification. TLC was
performed with plates from Merck KGaA (silica gel 60
F254). For purification via flash chromatography (FC) silica
gel 60 (40–63 µm mesh size) from Merck KGaA was
employed. Purification by preparative RP-MPLC was per-
formed using an Büchi instrument (C-605 binary pump
system, C-630 UV detector at 254 nm and C-660 fraction
collector) and a Sepacore glass column B-685 (26 ×
230 mm) equipped with YMC Gel Triart Prep C18-S
(12 nm, 5–20 µm). Melting points were determined with a
BÜCHI 510 melting point apparatus and are uncorrected.
Infrared spectra were recorded with a Perkin Elmer Paragon
1000 and a Jasco FT/IR-410. Solid substances were
10 rac-11
Fig. 3 General structure of the polycycles 10 to be used as starting
material for the construction of the desired GAT inhibitors rac-11
Tiagabine (6)
pIC50 = 6.88 ± 0.12 (mGAT1)
pIC50 = 73% (mGAT4)
Kragler et al. [55]
NO711 (7)
pIC50 = 6.83 ± 0.06 (mGAT1)
pIC50 = 3.07 ± 0.05 (mGAT4)
Kragler et al. [55]
(S)-SNAP-5114 (8)
pIC50 = 4.07 ± 0.09 (mGAT1)
pIC50 = 5.71 ± 0.07 (mGAT4)
Pabel et al. [64]
Deramciclane (rac-9)
pIC50 = 4.59 (mGAT1)a
pIC50 = 4.34 (mGAT4)a
Dhar et al. [39]
Fig. 2 Structures of important GAT inhibitors. The inhibitory poten-
cies for mGAT1 and mGAT4 are given as pIC50 ± SEM (if deter-
mined), that have been obtained in [3H]GABA uptake assays and
reported literature. Percentage values represent the remaining [3H]
GABA uptake at a concentration of 100 µM test compound. aThe
values refer to the human GAT subtypes hGAT1 and hGAT3
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measured as KBr pellets and oils as film on NaCl. HRMS
were obtained with a Finnigan MAT 95 (EI) and a Finnigan
LTQ FT (ESI). 1H and 13C NMR spectra were acquired
with a Avance III HD Bruker BioSpin (400 or 500MHz),
referenced to the solvent residual peak as internal
standard [53] and analyzed with MestReNova (Version
12.0.0–20080; Mestrelab Research S.L.; released
26.09.2017) . Nonequivalent protons attached to the same
carbon center were differentiated by superscript a and b
(e.g., NCH2
a, NCH2
b). The purity of the biologically tested
compounds was determined by quantitative 1H NMR (qH
NMR) according to a method described by Pauli et al. with
internal calibration [54]. The qH NMR measurements were
carried out under conditions allowing complete relaxation to
assure the exact determination of peak area ratios. Used
internal standards were benzyl benzoate (LOT# BCBN
6347V; purity 99.43%) and 1,3,5-trimethoxy benzene
(LOT# BCBW 3670; purity 99.96%) in CDCl3, CD2Cl2,
CD3OD or CD3OD+ 1M NaOD in D2O (6:1). All tested
esters had a purity >95%. The tested carboxylic acids
contained varying amounts of water which was not con-
sidered an impurity as the acids were dissolved in aqueous
media later on to perform the assays. The amount of water
was identified by qH NMR and calculated from the change
of the peak area ratio of the exchangeable protons (water
peak) to the solvent residual protons compared to the same
peak area ratio determined for pure solvent. In due con-
sideration of the amount of water contained, the purity of all
carboxylic acids was >95% with exception of the biologi-
cally inactive acids rac-18b and rac-11m, for which no
purity was determined.
General procedures
Synthesis of ethyl nipecotate precursors rac-15a–15f
(general procedure/GP1)
Potassium carbonate and sodium iodide were added to a
solution of racemic ethyl nipecotate rac-16 (1.0 equiv) in
the solvent stated. The organic halide was added to this
mixture that was stirred for the time period and at the
temperature indicated in the respective experiment. The
mixture was concentrated under vacuum, dissolved in ethyl
acetate, and washed with water. Drying of the organic phase
(Na2SO4) and removal of the solvent under vacuum affor-
ded the crude product which was purified by FC.
Deprotection and reductive amination of the dimethoxy
protected aldehydes rac-15e–15f with tricyclic imines
10a–10d (general procedure/GP2)
Part A: The tricyclic imine was dissolved in CH2Cl2
(15 mL/mmol) and sodium triacetoxyborohydride (2.5
equiv) and acetic acid (2.1 equiv) were added. The solution
was stirred at 20 °C for 45 min.
Part B: In the meantime, the dimethoxy acetal (2.0
equiv) was dissolved in CH2Cl2 (16 mL/mmol), and FeCl3 ∙
6 H2O was added. The acetal/salt suspension was rotated on
a rotary evaporator at 45 °C (no vacuum) for 20 min. In
doing so, the total volume was maintained by regular sol-
vent addition. The suspension was quenched with con-
centrated aqueous NaHCO3, extracted with CH2Cl2
(stabilized with amylene) for three times, dried (Na2SO4),
and concentrated under vacuum. The remaining crude
aldehyde was dissolved in CH2Cl2 (6.25 mL/mmolAcetal),
added to the imine/triacetoxyborohydride solution and
stirred for the time period and at the temperature stated in
the experiment. The reaction was quenched with potassium
carbonate solution (1 mol/L), extracted with CH2Cl2 for
three times, dried (Na2SO4), and concentrated under
vacuum to afford the crude product which was finally
purified by FC (SiO2, EtOAc/MeOH/NEt3 88:10:2) and, if
denoted, by RP-MPLC (DCM/MeOH 1:1).
Deprotection and reductive amination of the dimethoxy
protected aldehydes rac-15e–15f with tricyclic imines
10e–10f (general procedure/GP3)
Part A: The tricyclic imine was dissolved in MeOH
(13.3 mL/mmol) and sodium cyanoborohydride (5 equiv)
and hydrochloric acid (1 mol/L in Et2O, 10 equiv) were
added. The solution was stirred at 20 °C for 3 h. The
reaction was quenched with water, adjusted to pH= 11
with K2CO3 and the crude amine was extracted with
CH2Cl2 for three times. After drying (Na2SO4) and
removal of the solvent under vacuum the crude amine was
dissolved in CH2Cl2 (15 mL/mmol) again and sodium
triacetoxyborohydride (2.5 equiv) and acetic acid (2.1
equiv) were added.
Part B: Identical with Part B from GP2.
Hydrolysis of the N-substituted nipecotic acid ethyl esters
(general procedure/GP4)
The ester (1 equiv) was dissolved in MeOH (23 mL/mmol)
and successively H2O (5.7 mL/mmol) and Ba(OH)2 ∙ 8 H2O
(4 equiv) were added. The mixture was stirred at 20 °C for
16 h. Then CO2 was bubbled through the solution until all
barium carbonate had precipitated and pH= 8 was reached.
The suspension was diluted with MeOH (28.7 mL/mmol)
and for all experiments with ≥0.1 mmol nipecotic acid ethyl
ester the suspension was centrifuged (20 min, 3000 g) and
the clear supernatant filtered via a syringe filter (PTFE,
0.2 µm pore size). For experiments carried out with
≤0.1 mmol nipecotic acid ethyl ester the centrifugation step
was omitted. The solvent was removed under vacuum and
Medicinal Chemistry Research (2021) 30:586–609 589




According to GP4: Ester rac-19a (10 mg, 29 µmol, 1.0
equiv) and Ba(OH)2 ∙ 8 H2O (36 mg, 0.12 mmol, 4 equiv).
The product was obtained as colorless oil (8 mg, 87%). IR
(film) ~v= 3398, 2937, 2858, 2800, 1587, 1450, 1398,
1375, 1217, 1151, 1126, 1099 cm−1; 1H NMR (500 MHz,
CD3OD): δ= 3.52 (s, 1 H, CHN), 3.25 (dd, J= 13.3/
2.3 Hz, 1 H, CHNCH2
aCH), 3.21–3.11 (m, 3 H,
CHNCH2CH2, CHNCH2
bCH), 3.11–3.01 (m, 1 H,
OCCHCH2
aN), 2.91–2.83 (m, 1 H, CHCH2CH2CH2
a),
2.70–2.59 (m, 2 H, CHN(CH2)2CH2), 2.45–2.33 (m, 2 H,
OCCHCH2
bN, OCCH), 2.33–2.21 (m, 1 H,
CHCH2CH2CH2
b), 1.97–1.74 (m, 8 H, CHNCH2CH2,
NCH(CH2)2, CHCH2
aCH2, CHCH2CH2
a), 1.71–1.64 (m, 2
H, CCH2
aC, CHNCH2CH), 1.64–1.52 (m, 2 H,
CHCH2
bCH2, CHCH2CH2
b), 1.50 (d, J= 9.1 Hz, 1 H,
CCH2
bC), 1.10 (s, 3 H, CH3), 1.09 (s, 3 H, CH3) ppm;
13C
NMR (125 MHz, CD3OD) δ= 181.6 (CO), 58.3 (CHN
(CH2)2CH2), 58.0 (OCCHCH2N), 57.4 (CHNCH2CH2),
56.0 (NCH), 55.4 (CHCH2CH2CH2), 50.7 (CCH2C), 47.9
(CHNCH2CH), 45.8 (OCCH), 43.7 (CHNCH2CH), 37.5
(NCHCH2), 37.2 (NCHCH2), 36.5 (CCH3), 36.3 (CCH3),
28.6 (CHCH2CH2), 25.7 (CHCH2CH2), 24.9 (CH3), 24.9
(CH3), 22.0 (CHNCH2CH2) ppm; HRESIMS m/z (pos):
321.2534 C19H33N2O2 (calcd. 321.2537).
rac-1-[3-(1,7-Diphenyl-4-azatricyclo[3.3.1.02,7]nonan-4-yl)
propyl]piperidine-3-carboxylic acid rac-11b
According to GP4: Ester rac-19b (14 mg, 30 µmol, 1.0
equiv) and Ba(OH)2 ∙ 8 H2O (37 mg, 0.12 mmol, 4 equiv).
The product was obtained as colorless viscous oil (12 mg,
91%). IR (film) ~v= 3456, 3057, 3024, 2927, 2854, 2804,
1574, 1495, 1446, 1402, 1333, 1155, 1030, 758, 698 cm−1;
1H NMR (500MHz, CD3OD): δ= 7.37–7.29 (m, 4 H,
CCHCH), 7.29–7.24 (m, 4 H, CCHCH), 7.18 (t, J= 7.1
Hz, 2 H, CCHCHCH), 3.29 (d, J= 2.3 Hz, 2 H,
CHNCH2CH), 3.24 (br s, 1 H, CHN), 3.17 (d, J= 10.4 Hz,
1 H, NCH2
aCHCO), 2.98 (d, J= 11.5 Hz, 1 H,
CHCH2CH2CH2
a), 2.85–2.70 (m, 2 H, CHNCH2CH2),
2.70–2.54 (m, 3 H, CHNCH2CH, CHN(CH2)2CH2), 2.45








b), 2.01–1.90 (m, 1 H,
CHCH2
aCH2), 1.85 (p, J= 7.4 Hz, 2 H, CHNCH2CH2),
1.76 (dp, J= 13.7/3.7 Hz, 1 H, CHCH2CH2a), 1.67–1.54
(m, 1 H, CHCH2CH2
b), 1.54–1.41 (m, 1 H, CHCH2
bCH2)
ppm; 13C NMR (125MHz, CD3OD) δ= 181.8 (CO), 149.5
(CCHCH), 129.6 (CCHCH), 127.1 (CCHCHCH), 125.9
(CCHCH), 58.0 (CHN(CH2)2CH2), 57.9 (OCCHCH2N),
56.3 (CHNCH2CH2), 54.9 (CHCH2CH2CH2), 54.6 (NCH),
50.3 (CHNCH2CH), 50.0 (CCH2C), 45.5 (OCCH), 43.9
(CHNCH2CH), 43.1 (CCH2C), 40.4 (NCHCH2), 40.3
(NCHCH2), 28.8 (CHCH2CH2), 25.3 (CHCH2CH2), 24.8




According to GP4: Ester rac-19c (20 mg, 55 µmol, 1.0
equiv) and Ba(OH)2 ∙ 8 H2O (70 mg, 0.22 mmol, 4 equiv).
The product was obtained as yellow oil (13 mg, 70%). IR
(film) ~v= 3398, 2943, 2864, 2806, 1574, 1471, 1452, 1396,
1184, 1155, 1095, 951 cm−1; 1H NMR (500MHz,
CD3OD): δ= 3.23–3.05 (m, 4 H, NCH, CHNCH2CH,
OCCHCH2
aN) 2.98 (t, J= 7.2 Hz, 2 H, CHNCH2CH2),
2.90 (d, J= 11.3 Hz, 1 H, CHCH2CH2CH2a), 2.66–2.50 (m,
2 H, CHN(CH2)2CH2), 2.41 (t, J= 10.4/3.7 Hz, 1 H,
OCCH), 2.27 (t, J= 9.7 Hz, 1 H, OCCHCH2bN), 2.23–2.13
(m, 1 H, CHCH2CH2CH2
b), 2.00–1.88 (m, 3 H, NCH(CH2
a)2,
CHCH2
aCH2), 1.86 (p, J= 7.2 Hz, 2 H, CHNCH2CH2),
1.80–1.73 (m, 1 H, CHCH2CH2




b, CCH2CH2C), 1.18 (d,
J= 1.8 Hz, 6 H, CH3), 1.14 (s, 1 H, CHNCH2CH) ppm; 13C
NMR (125MHz, CD3OD) δ= 181.9 (CO), 57.9 (CHN
(CH2)2CH2), 57.9 (OCCHCH2N), 55.9 (CHNCH2CH2),
55.2 (CHCH2CH2CH2), 53.9 (NCH), 48.8 (CHNCH2CH),
46.3 (CHNCH2CH), 45.9 (OCCH), 41.1 (CCH2CH2C),
40.5 (NCHCbH2), 40.4 (NCHC
aH2), 39.8 (CCH3), 28.9
(CHCH2CH2), 26.2 (CH3), 25.7 (CHCH2CH2), 22.8




According to GP4: Ester rac-19d (19 mg, 39 µmol, 1.0
equiv) and Ba(OH)2 ∙ 8 H2O (49 mg, 0.16 mmol, 4 equiv).
The product was obtained as colorless oil (15 mg, 84%). IR
(film) ~v= 3452, 3055, 2945, 2868, 2810, 1579, 1495, 1444,
1396, 1153, 1105, 1030, 760, 700 cm−1; 1H NMR
(500MHz, CD3OD): δ= 7.50–7.44 (m, 4 H, CCHCH),
7.42–7.36 (m, 4 H, CCHCH), 7.25–7.20 (m, 2 H,
CCHCHCH), 3.24 (s, 1 H, NCH), 3.14–3.02 (m, 3 H,
CHNCH2CH, OCCHCH2
aN), 2.95 (s, 1 H, CHNCH2CH),
2.93–2.86 (m, 1 H, CHCH2CH2CH2
a), 2.80–2.65 (m, 4 H,
CHNCH2CH2, CHN(CH2)2CH2), 2.59 (dd, J= 14.4/2.4 Hz,
2 H, NCH(CH2
a)2), 2.47 (br s, 1 H, OCCHCH2
bN), 2.29 (br s,
1 H, CHCH2CH2CH2
b), 2.24–2.09 (m, 3 H, NCH(CH2
b)2,
OCCH), 2.05–1.86 (m, 4 H, CCH2CH2C), 1.72
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(p, J= 6.5 Hz, 2 H, CHNCH2CH2), 1.70–1.65 (m, 1 H,
CHCH2
aCH2), 1.57–1.47 (m, 1 H, CHCH2CH2
a), 1.47–1.36
(m, 1 H, CHCH2
bCH2), 1.13–0.98 (m, 1 H, CHCH2CH2
b)
ppm; 13C NMR (125MHz, CD3OD) δ= 180.4 (CO), 149.3
(CCHCH), 129.9 (CCHCaH), 129.8 (CCHCbH), 127.2
(CCHCHCH.), 126.8 (CC
aHCH), 126.8 (CCbHCH), 58.5
(CHN(CH2)2CH2), 57.5 (OCCHCH2N), 56.5




(CCH2CH2C), 44.3 (OCCH), 42.3 (CHNCH2CH), 42.0
(NCHCbH2), 41.7 (NCHC
aH2), 27.7 (CH2CH2CH), 24.1
(CHCH2CH2), 21.9 (CHNCH2CH2) ppm; HRESIMS m/z
(pos): 459.3002 C30H39N2O2 (calcd. 459.3006).
rac-1-[3-(3,7-Dimethyl-10-azatricyclo[5.3.1.03,8]undecan-10-
yl)propyl]piperidine-3-carboxylic acid rac-11e
According to GP4: Ester rac-19e (20 mg, 53 µmol, 1.0
equiv) and Ba(OH)2 ∙ 8 H2O (67 mg, 0.21 mmol, 4 equiv).
The product was obtained as yellow oil (15 mg, 81%). IR
(film) ~v= 3419, 2922, 1709, 1574, 1452, 1400, 1223, 1157,
1095, 953 cm−1; 1H NMR (500MHz, CD3OD): δ=
3.31–3.29 (m, 2 H, CHNCH2CH), 3.27 (s, 1 H, CHN), 3.11
(d, J= 10.9 Hz, 1 H, OCCHCH2aN), 3.04 (t, J= 7.3 Hz, 2
H, CHNCH2CH2), 2.90 (d, J= 11.4 Hz, 1 H,
CHCH2CH2CH2
a), 2.63–2.50 (m, 2 H, CHN(CH2)2CH2),
2.41 (tt, J= 10.6/3.7 Hz, 1 H, OCCH), 2.24 (t, J= 10.4 Hz,
1 H, OCCHCH2
bN), 2.17 (t, J= 10.4 Hz, 1 H,
CHCH2CH2CH2
b), 2.00–1.91 (m, 1 H, CHCH2
aCH2), 1.88
(p, J= 7.3 Hz, 2 H, CHNCH2CH2), 1.81–1.69 (m, 3 H,
NCH(CH2
a)2, CHCH2CH2





1.43–1.35 (m, 2 H, CCH2
aCH2CH2
aC), 1.21 (ddd, J= 13.4/
13.4/4.6 Hz, 2 H, CCH2
bCH2CH2
bC), 1.13 (s, 6 H, CH3),
0.97 (s, 1 H, CHNCH2CH) ppm;
13C NMR (125MHz,
CD3OD) δ= 182.0 (CO), 57.8 (OCCHCH2N), 57.7 (CHN
(CH2)2CH2), 55.7 (CHNCH2CH2), 55.3 (CHCH2CH2CH2),
54.9 (NCH), 48.1 (CHNCH2CH), 45.8 (OCCH), 45.4
(CHNCH2CH), 41.0 (CCH2CH2CH2C), 34.8 (NCH(CH2)2),
31.2 (CCH3), 30.4 (CH3), 29.0 (CHCH2CH2), 25.7
(CHCH2CH2), 23.1 (CHNCH2CH2), 19.7 (CCH2CH2) ppm;




According to GP4: Ester rac-19f (13 mg, 26 µmol, 1.0
equiv) and Ba(OH)2 ∙ 8 H2O (33 mg, 0.10 mmol, 4 equiv).
The product was obtained as colorless oil (9 mg, 73%). IR
(film) ~v= 3398, 2926, 2848, 2360, 2341, 1578, 1497, 1444,
1396, 1155, 1082, 1032, 758, 700 cm−1; 1H NMR
(500MHz, CD3OD): δ= 7.60–7.51 (m, 4 H, CCHCH),
7.45–7.37 (m, 4 H, CCHCH), 7.27–7.20 (m, 2 H,
CCHCHCH), 3.43 (s, 1 H, NCH), 3.12–2.90 (m, 4 H,
CHCH2NCH, CHNCH2CH, OCCHCH2
aN), 2.80 (d, J=
11.6 Hz, 1 H, CHCH2CH2CH2
a), 2.76–2.50 (m, 6 H, CHN
(CH2)2CH2, CHNCH2CH2, NCH(CH2
a)2), 2.32–2.12 (m, 3
H, NCH(CH2
b)2, OCCHCH2
bN), 2.06–1.84 (m, 3 H,
CCH2CH2
a, CHCH2CH2CH2




1.37–1.26 (m, 2 H, CHCH2
bCH2, CHCH2CH2
a), 0.74–0.53
(m, 1 H, CHCH2CH2
b) ppm; 13C NMR (125MHz, CD3OD)
δ= 180.7 (CO), 151.1 (CH2CCa), 150.9 (CH2CCb), 130.0
(CCHCaH), 129.9 (CCHCbH), 127.3(CCHCHCH.), 127.2
(CCaHCH), 127.2 (CCbHCH), 59.1 (CHN(CH2)2CH2), 58.4
(CHNCH2CH2), 58.1 (OCCHCH2N), 54.6 (NCH), 54.3
(CHCH2CH2CH2), 50.0 (CHNCH2CH), 45.0 (CC
aH2CH2),
45.0 (CCbH2CH2), 44.9 (OCCH), 40.1 (C
aCH2), 40.1
(CbCH2), 36.9 (CHNCH2CH), 35.9 (NCHC
aH2), 34.5
(NCHCbH2), 28.0 (CH2CH2CH), 24.3 (CHCH2CH2), 21.2
(CHNCH2CH2), 21.0 (CCH2CH2) ppm; HRESIMS m/z
(pos): 473.3157 C31H41N2O2 (calcd. 473.3163).
rac-1-[4-(1,7-Dimethyl-4-azatricyclo[3.3.1.02,7]nonan-4-yl)
butyl]piperidine-3-carboxylic acid rac-11g
According to GP4: Ester rac-19g (28 mg, 77 µmol, 1.0
equiv) and Ba(OH)2 ∙ 8 H2O (97 mg, 0.31 mmol, 4 equiv).
The product was obtained as yellow oil (20 mg, 77%). IR
(film) ~v= 3408, 2927, 2860, 2800, 1589, 1454, 1379, 1155,
1095, 1025, 939, 731 cm−1; 1H NMR (500MHz, CD3OD):
δ= 3.19–3.09 (m, 1 H, OCCHCH2aN), 2.96‒2.83 (m, 2 H,
CHCH2CH2CH2
a, CHN), 2.73 (d, J= 2.4 Hz, 2 H,
CHNCH2CH), 2.63–2.47 (m, 2 H, CHNCH2CH2),
2.46–2.29 (m, 3 H, CHN(CH2)3CH2, OCCH), 2.09–1.96
(m, 2 H, CHCH2
aCH2, OCCHCH2
bN), 1.92 (ddd, J= 11.8/
11.8/2.5 Hz, 1 H, CHCH2CH2CH2
b), 1.83 (d, J= 13.3 Hz, 2
H, NCH(CH2
a)2), 1.75–1.67 (m, 1 H, CHCH2CH2
a),




b)2), 1.41 (s, 1 H, CHNCH2CH),
1.40–1.31 (m, 2 H, CCH2
bC, CHCH2
bCH2), 1.01 (s, 6 H,
CH3) ppm;
13C NMR (125MHz, CD2Cl2) δ= 182.6 (CO),
60.1 (CHN(CH2)3CH2), 58.2 (OCCHCH2N), 57.8
(CHNCH2CH2), 55.0 (CHCH2CH2CH2), 53.8 (NCH), 51.8
(CCH2C), 48.1 (CHNCH2CH), 46.3 (OCCH), 45.8
(CHNCH2CH), 39.1 (NCH(CH2)2), 36.6 (CCH3), 29.5
(CHCH2CH2), 26.9 (CHNCH2CH2CH2), 26.0
(CHCH2CH2), 25.5 (CHNCH2CH2, CH3) ppm; HRESIMS
m/z (pos): 335.2695 C20H35N2O2 (calcd. 335.2693).
rac-1-[4-(1,7-Diphenyl-4-azatricyclo[3.3.1.02,7]nonan-4-yl)
butyl]piperidine-3-carboxylic acid rac-11h
According to GP4: Ester rac-19h (14 mg, 29 µmol, 1.0
equiv) and Ba(OH)2 ∙ 8 H2O (36 mg, 0.12 mmol, 4 equiv).
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The product was obtained as colorless viscous oil (13 mg,
98%). IR (KBr) ~v= 3419, 3057, 3024, 2933, 2858, 2800,
1601, 1495, 1446, 1387, 1155, 1030, 760, 700, 536 cm−1;
1H NMR (500 MHz, CD3OD): δ= 7.36–7.31 (m, 4 H,
CCHCH), 7.31–7.25 (m, 4 H, CCHCH), 7.23–7.17 (m, 2
H, CCHCHCH), 3.45 (br s, 1 H, CHN), 3.42 (d, J=
2.2 Hz, 2 H, CHNCH2CH), 3.11 (d, J= 10.5 Hz, 1 H,
NCH2
aCHCO), 3.08–2.78 (m, 7 H, NCH2CH2CH2CH2N,
CHCH2CH2CH2, NCH2
bCHCO), 2.75 (s, 1 H,
CHNCH2CH), 2.60–2.52 (m, 1 H, CHCO), 2.44–2.33
(m, 3 H, CCH2
aC, NCH(CH2
a)2), 2.29 (dd, J= 14.0/
3.2 Hz, 2 H, NCH(CH2
b)2), 2.23 (d, J= 8.9 Hz, 1 H,
CCH2
bC), 1.93–1.81 (m, 2 H, CHCH2CH2
a, CHCH2
aCH2),




13C NMR (125 MHz, CD3OD)
δ= 180.4 (CO), 148.8 (CCHCH), 129.7 (CCHCH), 127.4
(CCHCHCH), 125.9 (CCHCH), 58.2 (CHN(CH2)3CH2),
57.0 (CHNCH2CH2), 56.2 (OCCHCH2N), 55.0 (NCH),
54.8 (CHCH2CH2CH2), 50.3 (CHNCH2CH), 50.0
(CCH2C), 43.2 (OCCH), 43.0 (CHNCH2CH), 42.9
(CCH2C), 39.5 (NCH(CH2)2), 27.4 (CHCH2CH2), 25.1
(CHNCH2CH2CH2)*, 23.5 (CHNCH2CH2)*, 23.5
(CHCH2CH2) ppm; Signals indicated by asterisk cannot
be assigned unambiguously and are interchangeable.




According to GP4: Ester rac-19j (20 mg, 53 µmol, 1.0
equiv) and Ba(OH)2 ∙ 8 H2O (67 mg, 0.21 mmol, 4 equiv).
The product was obtained as yellow oil (18 mg, 97%). IR
(film) ~v= 3398, 2943, 2866, 2800, 1579, 1471, 1450,
1396, 1180, 1155, 1093 cm−1; 1H NMR (400 MHz,
CD2Cl2): δ= 10.77 (br s, 1 H, COOH), 3.06–2.87 (m,
4 H, NCH, CHNCH2CH, OCCHCH2
aN), 2.78–2.63 (m, 3
H, CHNCH2CH2, CHCH2CH2CH2
a), 2.47–2.31 (m, 3 H,
CHN(CH2)3CH2, OCCH), 2.26–2.07 (m, 2 H,
CHCH2CH2CH2
b, OCCHCH2
bN), 1.97–1.81 (m, 3 H,
NCH(CH2
a)2, CHCH2
aCH2), 1.75–1.65 (m, 1 H,
CHCH2CH2
a), 1.65–1.39 (m, 10 H, CHCH2
bCH2,
CHCH2CH2
b, NCH2CH2CH2CH2N, CCH2CH2C), 1.34
(dd, J= 13.9/1.9 Hz, 2 H, NCH(CH2b)2), 1.13 (s, 6 H,
CH3), 1.00 (s, 1 H, CHNCH2CH) ppm;
13C NMR
(100MHz, CD2Cl2) δ= 178.8 (CO), 58.3 (CHN(CH2)3CH2),
56.7 (CHNCH2CH2), 54.9 (OCCHCH2N), 54.3
(CHCH2CH2CH2), 51.4 (NCH), 48.5 (CHNCH2CH), 44.7
(CHNCH2CH), 43.4 (OCCH), 40.6 (CCH2CH2C), 40.0
(NCH(CH2)2), 39.2 (CCH3), 28.1 (CHCH2CH2), 26.1
(CH3), 24.8 (CHCH2CH2), 24.2 (CHNCH2CH2), 24.0




According to GP4: Ester rac-19k (13 mg, 26 µmol, 1.0
equiv) and Ba(OH)2 ∙ 8 H2O (33 mg, 0.10 mmol, 4 equiv).
The product was obtained as colorless viscous oil (8 mg,
65%). IR (film) ~v= 3398, 3054, 2943, 2866, 2802, 1651,
1587, 1495, 1444, 1394, 1153, 1105, 1032, 760, 702 cm−1;
1H NMR (500MHz, CD3OD): δ= 7.49–7.43 (m, 4 H,
CCHCH), 7.39–7.33 (m, 4 H, CCHCH), 7.23–7.17 (m, 2 H,
CCHCHCH), 3.02 (d, J= 9.1 Hz, 1 H, OCCHCH2aN), 2.98
(s, 1 H, NCH), 2.96–2.88 (m, 2 H, CHNCH2CH), 2.85–2.77
(m, 2 H, CHCH2CH2CH2
a, CHNCH2CH), 2.56 (dt, J=
13.9/2.6 Hz, 2 H, NCH(CH2
a)2), 2.53–2.44 (m, 2 H, CHN
(CH2)3CH2), 2.44–2.30 (m, 4 H, OCCHCH2
bN, OCCH,
CHNCH2CH2), 2.25–2.16 (m, 1 H, CHCH2CH2CH2
b),
2.08 (dt, J= 13.9/2.6 Hz, 2 H, NCH(CH2b)2), 2.01–1.84 (m,
5 H, CHCH2
aCH2, CCH2CH2C), 1.73–1.65 (m, 1 H,
CHCH2CH2
a), 1.58–1.38 (m, 6 H, CHCH2
bCH2,
NCH2CH2CH2CH2N, CHCH2CH2
b) ppm; 13C NMR
(125MHz, CD3OD) δ= 181.5 (CO), 150.1 (CCHCH),
129.6 (CCHCH), 126.8 (CCHCH), 126.8 (CCHCHCH.),
59.0 (CHN(CH2)3CH2), 57.1 (OCCHCH2N), 56.3
(CHNCH2CH2), 54.8 (CHCH2CH2CH2), 52.4 (NCH), 47.6
(CaCH2), 47.5 (C
bCH2), 47.4 (CHNCH2CH), 44.8 (OCCH),
44.3 (CCH2CH2C), 43.0 (CHNCH2CH), 42.3 (NCHC
aH2),
42.2 (NCHCbH2), 28.5 (CH2CH2CH), 25.6 (CHNCH2CH2),
24.7 (CHNCH2CH2CH2), 24.5 (CHCH2CH2) ppm; HRE-
SIMS m/z (pos): 473.3164 C31H41N2O2 (calcd. 473.3163).
rac-1-[4-(3,7-Dimethyl-10-azatricyclo[5.3.1.03,8]undecan-10-
yl)butyl]piperidine-3-carboxylic acid rac-11l
According to GP4: Ester rac-19l (17 mg, 44 µmol, 1.0
equiv) and Ba(OH)2 ∙ 8 H2O (55 mg, 0.17 mmol, 4 equiv).
The product was obtained as colorless viscous oil (15 mg,
96%). IR (film) ~v= 3398, 2924, 2800, 1583, 1454, 1390,
1157, 1097, 1026, 953, 770 cm−1; 1H NMR (400MHz,
CD2Cl2): δ= 9.02 (br s, 1 H, COOH), 3.26–3.08 (m, 3 H,
CHN, CHNCH2CH), 2.97 (d, J= 10.2 Hz, 1 H, OCCH-
CH2
aN), 2.89–2.76 (m, 2 H, CHNCH2CH2), 2.76–2.64 (m,
1 H, CHCH2CH2CH2
a), 2.48–2.31 (m, 3 H, OCCH,
CHN(CH2)3CH2), 2.27–2.03 (m, 2 H, CHCH2CH2CH2
b,
OCCHCH2
bN), 1.94–1.83 (m, 1 H, CHCH2
aCH2), 1.75 (dd,






CHCH2CH2, NCH2CH2CH2CH2N, CCH2CH2), 1.14 (ddd,
J= 13.1/13.1/5.5 Hz, 2 H, CCH2bCH2CH2bC), 1.09 (s, 6 H,
CH3), 0.84 (s, 1 H, CHNCH2CH) ppm;
13C NMR
(100MHz, CD2Cl2) δ= 179.0 (CO), 58.2 (CHN(CH2)
3CH2), 56.7 (OCCHCH2N), 54.9 (CHNCH2CH2), 54.4
(CHCH2CH2CH2), 52.4 (NCH), 46.3 (CHNCH2CH), 44.9
(CHNCH2CH), 43.5 (OCCH), 40.4 (CCH2CH2CH2C), 34.0
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(NCH(CH2)2), 30.6 (CCH3), 30.1 (CH3), 28.2
(CHCH2CH2), 24.9 (CHCH2CH2), 24.2 (CHN(CH2)2CH2)*,
23.9 (CHNCH2CH2)*, 19.2 (CCH2CH2) ppm; Signals
indicated by asterisk cannot be assigned unambiguously and




According to GP4: Ester rac-19m (12 mg, 23 µmol, 1.0
equiv) and Ba(OH)2 ∙ 8 H2O (29mg, 92 µmol, 4 equiv). The
product was obtained as colorless oil (6 mg, 53%). IR (film)
~v= 3390, 3055, 2926, 2852, 2800, 1595, 1495, 1444, 1402,
1155, 1099, 1032, 756, 700 cm−1; 1H NMR (500MHz,
CD3OD): δ= 7.54 (d, J= 8.3 Hz, 4 H, CCHCH), 7.44–7.34
(m, 4 H, CCHCH), 7.21 (t, J= 7.3 Hz, 2 H, CCHCHCH),
3.23 (s, 1 H, NCH), 2.95 (d, J= 8.4 Hz, 1 H, OCCHCH2aN),
2.92–2.84 (m, 2 H, CHNCH2CH), 2.82 (s, 1 H,
CHCH2NCH), 2.78–2.73 (m, 1 H, CHCH2CH2CH2
a),
2.73–2.64 (m, 2 H, NCH(CH2
a)2), 2.52–2.28 (m, 6 H,
OCCHCH2
bN, CHN(CH2)3CH2, CHNCH2CH2, OCCH),
2.28–2.18 (m, 1 H, CHCH2CH2CH2
b), 2.14 (ddd, J= 14.6/
5.6/2.3 Hz, 2 H, NCH(CH2
b)2), 1.99–1.90 (m, 1 H,
CCH2CH2
a), 1.89–1.82 (m, 1 H, CHCH2
aCH2), 1.72–1.59











13C NMR (125MHz, CD3OD) δ= 181.3 (CO), 151.5
(CH2CC), 129.7 (CCHCH), 127.2 (CCHCH), 127.0
(CCHCHCH.), 58.4 (CHN(CH2)3CH2), 56.9 (OCCHCH2N),
56.5 (CHNCH2CH2), 54.7 (CHCH2CH2CH2), 53.0 (NCH),
50.0 (CHNCH2CH), 45.0 (CCH2CH2CH2C), 44.5 (OCCH),
40.3 (CCH2), 37.5 (CHNCH2CH), 35.3 (NCHC
aH2), 35.1
(NCHCbH2), 28.3 (CH2CH2CH), 24.9 (CHNCH2CH2), 24.5
(CHCH2CH2), 24.1 (CHN(CH2)2CH2), 21.1 (CCH2CH2)




Synthesis according to literature [39].
rac-Ethyl 1-(4-hydroxybutyl)piperidine-3-carboxylate rac-
15b
According to GP1: Reaction under exclusion of oxygen
and light with potassium carbonate (4.15 g, 30.0 mmol, 3.0
equiv), sodium iodide (19 mg, 0.13 mmol, 0.01 equiv),
ethyl nipecotate rac-16 (1.57 g, 10.0 mmol, 1.6 mL, 1.0
equiv) and 4-bromobutan-1-ol (2.30 g, 15.0 mmol, 1.5
equiv) (no solvent used; the mixture was cooled to 0 °C
prior to the halide addition). The temperature was kept at
0 °C for 6 h, then at 20 °C for 42 h. FC (SiO2, CH2Cl2/
MeOH/NEt3 93:5:2). The product was obtained as color-
less oil (2.18 g, 95%). IR (film): ~v= 3390, 2939, 2868,
2810, 2775, 1732, 1470, 1446, 1371, 1311, 1182, 1151,
1032, 862 cm–1; 1H NMR (400 MHz, CDCl3): δ= 4.11
(dq, J= 7.2/0.5 Hz, 2 H, CH2CH3), 3.59–3.50 (m, 2 H,
CH2OH), 3.08 (d, J= 11.3 Hz, 1 H, NCH2aCH), 2.86 (d,
J= 11.3 Hz, 1 H, CHCH2CH2CH2a), 2.59 (tt, J= 11.1/
3.9 Hz, 1 H, CHCO), 2.43–2.34 (m, 2 H, NCH2(CH2)3
OH), 2.13 (t, J= 11.1 Hz, 1 H, NCH2bCH), 2.03–1.92 (m,
2 H, NCH2CHCH2
a, CHCH2CH2CH2
b), 1.77–1.54 (m, 6 H,
CHCH2CH2, CH2CH2CH2OH), 1.40 (dq, J= 12.0/4.3 Hz, 1
H, NCH2CHCH2
b), 1.23 (t, J= 7.2 Hz, 3 H, CH3) ppm; 13C
NMR (100MHz, CDCl3): δ= 173.9 (CO), 62.8 (CH2OH),
60.6 (CH2CH3), 59.0 (CH2(CH2)3OH), 55.3 (CHCH2N),
53.7 (CHCH2CH2CH2), 41.5 (CHCO), 32.7 (CH2CH2OH),
27.1 (CHCH2CH2), 25.6 (CH2CH2CH2OH), 24.4
(CHCH2CH2), 14.3 (CH3) ppm; HREIMS m/z [M]
+:
229.1692 C12H23NO3 (calcd. 229.1672).
rac-Ethyl 1-[2-(1,3-dioxolan-2-yl)ethyl]piperidine-3-
carboxylate rac-15c
According to GP1: Potassium carbonate (9.12 g,
66.0 mmol, 3.3 equiv), sodium iodide (41 mg, 0.28 mmol,
0.01 equiv), ethyl nipecotate rac-16 (3.14 g, 20.0 mmol,
3.1 mL, 1.0 equiv) and 2-(2-bromoethyl)-1,3-dioxolane
(3.98 g, 22.0 mmol, 2.6 mL, 1.1 equiv) (no solvent used;
the mixture was cooled to 0 °C prior to the halide addi-
tion). The temperature was kept at 0 °C for 3 h, then at
20 °C for 48 h. FC (SiO2, CH2Cl2/MeOH/NEt3 93:5:2).
The product was obtained as yellow oil (4.79 g, 93%). IR
(film) ~v= 2943, 2885, 2773, 1730, 1470, 1373, 1309,
1180, 1140, 1032, 945, 912, 800 cm−1; 1H NMR
(400 MHz, CDCl3): δ= 4.91 (t, J= 4.9 Hz, 1 H, OCH),
4.11 (q, J= 7.1 Hz, 2 H, CH2CH3), 4.00–3.76 (m, 4 H,
OCH2CH2O), 3.03–2.91 (m, 1 H, NCH2
aCH), 2.76
(dt, J= 11.2/3.6 Hz, 1 H, NCH2aCH2CH2), 2.59–2.45 (m,
3 H, NCH2CH, OCHCH2CH2), 2.14 (t, J= 10.7 Hz,
1 H, NCH2
bCH), 2.04–1.80 (m, 4 H, OCHCH2,
NCH2
bCH2CH2, NCH2CHCH2
a), 1.76–1.65 (m, 1 H,
NCH2CH2
aCH2), 1.61–1.49 (m, 1 H, NCH2CH2
bCH2),
1.42 (dq, J= 11.9/3.9 Hz, 1 H, NCH2CHCH2b), 1.24 (t,
J= 7.1 Hz, 3 H, CH3) ppm; 13C NMR (100MHz, CDCl3):
δ= 174.3 (CO), 103.5 (OCH), 65.0 (OCH2CH2O), 60.4
(CH2CH3), 55.6 (NCH2CH), 53.9 (NCH2CH2CH2), 53.7
(OCHCH2CH2), 42.1 (NCH2CH), 31.5 (OCHCH2), 27.1
(NCH2CHCH2), 24.7 (NCH2CH2CH2), 14.4 (CH3) ppm;
HREIMS m/z [M]+: 257.1611 C13H23NO4 (calcd.
257.1622).
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rac-Ethyl 1-[3-(1,3-dioxolan-2-yl)propyl]piperidine-3-
carboxylate rac-15d
According to GP1: Potassium carbonate (4.15 g, 30.0mmol,
3.0 equiv), sodium iodide (19 mg, 0.13mmol, 0.01 equiv),
ethyl nipecotate rac-16 (1.57 g, 10.0mmol, 1.6 mL, 1.0
equiv) and 2-(3-chloropropyl)-1,3-dioxolane (1.66 g,
11.0mmol, 1.45mL, 1.1 equiv) in 1,4-dioxane (10 mL). The
temperature was kept at 100 °C for 82 h. FC (SiO2, CH2Cl2/
MeOH/NEt3 93:5:2). The product was obtained as yellow oil
(2.15 g, 79%). IR (film) ~v= 2945, 2877, 2806, 2769, 1730,
1470, 1446, 1371, 1309, 1209, 1180, 1151, 1034, 943, 862,
733 cm−1; 1H NMR (400MHz, CDCl3): δ= 4.87 (dt, J=
4.4/0.8 Hz, 1 H, OCH), 4.11 (dq, J= 7.1/0.6 Hz, 2 H,
CH2CH3), 4.01–3.77 (m, 4 H, OCH2CH2O), 2.98 (d, J=
11.0 Hz, 1 H, NCH2
aCH), 2.75 (d, J= 11.2 Hz, 1 H,
NCH2
aCH2CH2), 2.59–2.47 (m, 1 H, NCH2CH), 2.44–2.31
(m, 2 H, OCHCH2CH2CH2), 2.12 (t, J= 10.7 Hz, 1 H,
NCH2
bCH), 2.02–1.86 (m, 2 H, NCH2
bCH2CH2,
NCH2CHCH2
a), 1.75–1.49 (m, 6 H, NCH2CH2CH2,
OCHCH2, OCHCH2CH2), 1.42 (dq, J= 11.9/4.1 Hz, 1 H,
NCH2CHCH2
b), 1.24 (dt, J= 7.1/0.9 Hz, 3 H, CH3)
ppm; 13C NMR (100MHz, CDCl3): δ= 174.4 (CO), 104.6
(OCH), 65.0 (OCH2CH2O), 60.4 (CH2CH3), 58.7
(OCHCH2CH2CH2), 55.7 (NCH2CH), 53.8 (NCH2CH2CH2),
42.1 (NCH2CH), 31.9 (OCHCH2CH2), 27.2 (NCH2CHCH2),
24.8 (NCH2CH2CH2), 21.4 (OCHCH2), 14.4 (CH3) ppm;
HREIMS m/z [M]+: 271.1745 C14H25NO4 (calcd. 271.1778).
rac-Ethyl 1-(3,3-dimethoxypropyl)piperidine-3-carboxylate
rac-15e
According to GP1: Potassium carbonate (5.12 g,
37.0 mmol, 3.0 equiv), ethyl nipecotate rac-16 (1.93 g,
12.3 mmol, 1.9 mL, 1.0 equiv) and 3-bromo-1,1-dimethox-
ypropane (2.49 g, 13.6 mmol, 1.9 mL, 1.1 equiv) in acetone
(12 mL) (no sodium iodide was used). The temperature was
kept at 70 °C for 18 h. FC (SiO2, CH2Cl2/MeOH/NEt3
93:5:2). The product was obtained as yellow oil (2.17 g,
68%). IR (film) ~v= 2943, 2827, 2775, 1732, 1470, 1446,
1371, 1311, 1180, 1126, 1057, 964, 912, 862 cm−1; 1H
NMR (400MHz, CDCl3): δ= 4.43 (t, J= 5.7 Hz, 1 H,
OCH), 4.12 (q, J= 7.1 Hz, 2 H, CH2CH3), 3.31 (s, 6 H,
OCH3), 2.96 (d, J= 11.2 Hz, 1 H, NCH2aCH), 2.74 (d, J=
11.0 Hz, 1 H, NCH2
aCH2CH2), 2.60–2.49 (m, 1 H,
NCH2CH), 2.44–2.35 (m, 2 H, OCHCH2CH2), 2.15 (t, J=
10.6 Hz, 1 H, NCH2
bCH), 1.99 (dd, J= 11.0/2.7 Hz, 1 H,
NCH2
bCH2CH2), 1.95–1.87 (m, 1 H, NCH2CHCH2
a),
1.83–1.76 (m, 2 H, OCHCH2), 1.76–1.67 (m, 1 H,
NCH2CH2
aCH2), 1.62–1.49 (m, 1 H, NCH2CH2
bCH2),
1.49–1.37 (m, 1 H, NCH2CHCH2
b), 1.24 (t, J= 7.1 Hz, 3
H, CH2CH3) ppm;
13C NMR (100MHz, CDCl3): δ= 174.3
(CO), 103.5 (OCH), 60.4 (CH2CH3), 55.7 (NCH2CH), 54.2
(OCHCH2CH2), 54.0 (NCH2CH2CH2), 53.0 (OCH3), 42.1
(NCH2CH), 30.2 (OCHCH2), 27.1 (NCH2CHCH2), 24.8
(NCH2CH2CH2), 14.4 (CH3) ppm; HRESIMS m/z (pos):
260.1856 C13H26NO4 (calcd. 260.1856).
rac-Ethyl 1-(4,4-dimethoxybutyl)piperidine-3-carboxylate
rac-15f
According to GP1: Potassium carbonate (4.15 g, 30.0mmol,
3.0 equiv), sodium iodide (450mg, 3.00mmol, 0.3 equiv),
ethyl nipecotate rac-16 (1.57 g, 10.0mmol, 1.6 mL, 1.0
equiv) and 4-chloro-1,1-dimethoxybutane (1.68 g,
11.0mmol, 1.6 mL, 1.1 equiv) in acetone (10 mL). The
temperature was kept at 70 °C for 62 h. FC (SiO2, CH2Cl2/
MeOH/NEt3 94:5:1). The product was obtained as yellow oil
(2.02 g, 74%). IR (film) ~v= 2943, 2827, 2808, 2775, 1732,
1471, 1448, 1371, 1309, 1180, 1128, 1074, 1034, 962, 862,
794, 735 cm−1; 1H NMR (500MHz, CDCl3): δ= 4.36 (t,
J= 5.5 Hz, 1 H, OCH), 4.11 (q, J= 7.1 Hz, 2 H, CH2CH3),
3.30 (s, 6 H, OCH3), 2.97 (d, J= 10.7 Hz, 1 H, NCH2aCH),
2.75 (d, J= 11.1 Hz, 1 H, CCHCH2CH2CH2a), 2.53 (tt, J=
10.7/3.8 Hz, 1 H, NCH2CH), 2.36–2.30 (m, 2 H,
OCHCH2CH2CH2), 2.11 (t, J= 10.7 Hz, 1 H, NCH2bCH),
1.99–1.88 (m, 2 H, CCHCH2CH2CH2
b, NCH2CHCH2
a),
1.74–1.67 (m, 1 H, NCH2CHCH2CH2
a), 1.62–1.48 (m, 5 H,
NCH2CHCH2CH2
b, OCHCH2, OCHCH2CH2), 1.42 (dq, J=
13.3/3.8 Hz, 1 H, NCH2CHCH2
b), 1.24 (t, J= 7.1 Hz,
3 H, CH2CH3) ppm;
13C NMR (125MHz, CDCl3):
δ= 174.4 (CO), 104.6 (OCH), 60.4 (CH2CH3),
58.7 (OCHCH2CH2CH2), 55.6 (NCH2CH), 53.9
(CCHCH2CH2CH2), 52.8 (OCH3), 42.1 (NCH2CH), 30.6
(OCHCH2), 27.2 (NCH2CHCH2), 24.8 (NCH2CHCH2CH2),
22.1 (OCHCH2CH2), 14.4 (CH3) ppm; HREIMS m/z [M]
+:
273.1956 C14H27NO4 (calcd. 273.1935).
rac-1-(3-Hydroxypropyl)piperidine-3-carboxylic acid rac-18a
According to GP4: Ester rac-15a (150 mg, 0.697 mmol, 1.0
equiv) and Ba(OH)2 ∙ 8 H2O (880 mg, 2.79 mmol, 4 equiv).
The product was obtained as colorless viscous oil (109 mg,
84%). IR (KBr) ~v= 3394, 2951, 2871, 1589, 1450, 1392,
1068, 935, 773 cm–1; 1H NMR (400MHz, CD3OD/1 M
NaOD in D2O 6:1): δ= 3.60 (t, J= 6.3 Hz, 2 H, CH2OH),
3.16–3.05 (m, 1 H, NCH2
aCH), 2.91 (d, J= 11.0 Hz, 1 H,
CHCH2CH2CH2
a), 2.50–2.41 (m, 2 H, NCH2(CH2)2OH),






a, CH2CH2OH), 1.57 (tq, J= 12.9/3.8 Hz,
1 H, CHCH2CH2
b), 1.34 (dq, J= 12.7/4.0 Hz, 1 H,
CHCH2
bCH2) ppm;
13C NMR (100MHz, CD3OD/1 M
NaOD in D2O 6:1): δ= 183.0 (CO), 61.8 (CH2OH), 58.0
(CHCH2N), 57.1 (CH2(CH2)2OH), 54.8 (CHCH2CH2CH2),
46.3 (CHCO), 29.9 (CH2CH2OH), 29.3 (CHCH2CH2), 25.8
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(CHCH2CH2) ppm; HRESIMS m/z (pos): 188.1279
C9H18NO3 (calcd. 188.1281).
rac-1-(4-Hydroxybutyl)piperidine-3-carboxylic acid rac-18b
According to GP4: Ester rac-15b (80 mg, 0.35 mmol, 1.0
equiv) and Ba(OH)2 ∙ 8 H2O (442 mg, 1.40 mmol, 4 equiv).
The product was obtained as yellow viscous oil (50 mg,
71%). IR (film) ~v= 3348, 2940, 2868, 1714, 1589, 1448,
1392, 1061, 1026, 771 cm–1; 1H NMR (400MHz, CD3OD/
1 M NaOD in D2O 6:1): δ= 3.56 (t, J= 6.0 Hz, 2 H,
CH2OH), 3.17–3.08 (m, 1 H, NCH2
aCH), 2.91 (d, J=
11.1 Hz, 1 H, CHCH2CH2CH2
a), 2.43–2.30 (m, 3 H,




bCH), 1.75–1.66 (m, 1 H,
CHCH2CH2
a), 1.66–1.50 (m, 5 H, CHCH2CH2
b,
CH2CH2CH2OH), 1.34 (dq, J= 12.6/4.1 Hz, 1 H,
CHCH2
bCH2) ppm;
13C NMR (100MHz, CD3OD/1 M
NaOD in D2O 6:1): δ= 182.9 (CO), 62.8 (CH2OH), 59.9
(CH2(CH2)3OH), 57.9 (CHCH2N), 54.8 (CHCH2CH2CH2),
46.2 (CHCO), 32.0 (CH2CH2OH), 29.4 (CHCH2CH2), 25.8
(CHCH2CH2), 24.3 (CH2(CH2)2OH) ppm; HRESIMS m/z
(pos): 202.1436 C10H20NO3 (calcd. 202.1438).
rac-1-[2-(1,3-Dioxolan-2-yl)ethyl]piperidine-3-carboxylic
acid rac-18c
According to GP4: Ester rac-15c (150 mg, 0.583 mmol, 1.0
equiv) and Ba(OH)2 ∙ 8 H2O (735 mg, 2.33 mmol, 4 equiv).
The product was obtained as colorless viscous oil (118 mg,
88%). IR (KBr) ~v= 3419, 2954, 2893, 1589, 1450, 1390,
1140, 1030, 651, 771 cm–1; 1H NMR (400MHz, CD3OD/1
M NaOD in D2O 6:1): δ= 4.91–4.85 (m, 1 H, OCHO),
4.00–3.81 (m, 4 H, OCH2CH2O), 3.13–3.03 (m, 1 H,
NCH2
aCH), 2.88 (d, J= 11.0 Hz, 1 H, CHCH2CH2CH2a),
2.54–2.41 (m, 2 H, CH2CH2CHO), 2.36 (tt, J= 11.8/




bCH, CH2CHO), 1.75–1.66 (m, 1
H, CCHCH2CH2
a), 1.57 (tq, J= 12.9/3.8 Hz, 1 H,
CCHCH2CH2
b), 1.33 (dq, J= 12.7/4.1 Hz, 1 H,
CCHCH2
bCH2) ppm;
13C NMR (100MHz, CD3OD/1 M
NaOD in D2O 6:1): δ= 182.9 (CO), 104.3 (OCHO), 65.9
(OCH2CH2O), 57.9 (CHCH2N), 54.7 (CHCH2CH2CH2),
54.4 (CH2CH2CHO), 46.2 (CHCO), 31.6 (CH2CH2CHO),
29.3 (CHCH2CH2), 25.7 (CHCH2CH2) ppm; HRESIMS m/
z (pos): 230.1385 C11H20NO4 (calcd. 230.1387).
rac-1-[3-(1,3-Dioxolan-2-yl)propyl]piperidine-3-carboxylic
acid rac-18d
According to GP4: Ester rac-15d (150 mg, 0.553 mmol, 1.0
equiv) and Ba(OH)2 ∙ 8 H2O (697 mg, 2.21 mmol, 4 equiv).
The product was obtained as colorless solid (124 mg, 92%).
Mp 132 °C; IR (KBr) ~v= 3429, 2954, 2887, 1610, 1483,
1387, 1140, 1041, 962, 912, 822, 768, 700, 530 cm–1; 1H
NMR (400MHz, CD3OD/1 M NaOD in D2O 6:1): δ=
4.88–4.84 (m, 1 H, OCHO), 4.00–3.80 (m, 4 H, OCH2-
CH2O), 3.15–3.06 (m, 1 H, NCH2
aCH), 2.89 (d, J=
11.1 Hz, 1 H, CCH(CH2)2CH2
a), 2.44–2.31 (m, 3 H, CH2
(CH2)2CHO, CHCO), 2.05–1.94 (m, 2 H, CCHCH2
aCH2,
NCH2
bCH), 1.91 (ddd, J= 11.8/11.8/2.8 Hz, 1 H, CCH
(CH2)2CH2
b), 1.75–1.51 (m, 6 H, CCHCH2CH2,
NCH2CH2CH2CHO), 1.33 (dq, J= 12.6/4.1 Hz, 1 H,
CCHCH2
bCH2) ppm;
13C NMR (100MHz, CD3OD/1 M
NaOD in D2O 6:1): δ= 183.0 (CO), 105.3 (OCHO), 65.9
(OCH2CH2O), 59.9 (CH2(CH2)2CHO), 58.0 (CHCH2N),
54.7 (CCH(CH2)2CH2), 46.2 (CHCO), 32.8
(CH2CH2CHO), 29.4 (CCHCH2CH2), 25.8 (CCHCH2CH2),




According to GP4: Ester rac-15e (150 mg, 0.578 mmol, 1.0
equiv) and Ba(OH)2 ∙ 8 H2O (729 mg, 2.31 mmol, 4 equiv).
The product was obtained as colorless solid (57 mg, 43%).
Mp 124 °C; IR (KBr) ~v= 3435, 2951, 2834, 1601, 1450,
1385, 1192, 1128, 1053, 997, 947, 770, 704, 525 cm–1; 1H
NMR (400MHz, CD3OD/1 M NaOD in D2O 6:1): δ=
4.44 (t, J= 5.6 Hz, 1 H, OCHO), 3.34 (s, 6 H, OCH3),
3.12–3.04 (m, 1 H, NCH2
aCH), 2.87 (d, J= 11.0 Hz,
1 H, CHCH2CH2CH2
a), 2.46–2.30 (m, 3 H, CHCO,




bCH), 1.88–1.78 (m, 2 H,
CH2CHO), 1.75–1.66 (m, 1 H, CCHCH2CH2
a), 1.57 (tq,
J= 12.9/3.8 Hz, 1 H, CCHCH2CH2b), 1.33 (dq, J= 12.6/
4.1 Hz, 1 H, CCHCH2
bCH2) ppm;
13C NMR (100MHz,
CD3OD/1 M NaOD in D2O 6:1): δ= 182.9 (CO), 105.0
(OCHO), 58.0 (CHCH2N), 55.1 (CH2CH2CHO), 54.8
(CHCH2CH2CH2), 53.7 (OCH3), 46.2 (CHCO), 30.6
(CH2CHO), 29.3 (CCHCH2CH2), 25.8 (CCHCH2CH2)




According to GP4: Ester rac-15f (150 mg, 0.549 mmol, 1.0
equiv) and Ba(OH)2 ∙ 8 H2O (691 mg, 2.19 mmol, 4 equiv).
The product was obtained as colorless solid (85 mg, 63%).
Mp 99 °C; IR (KBr) ~v= 3433, 2945, 2831, 1601, 1456,
1385, 1126, 1072, 1049, 960, 768, 706 cm–1; 1H NMR
(400MHz, CD3OD/1 M NaOD in D2O 6:1): δ= 4.46–4.37
(m, 1 H, OCHO), 3.34 (s, 6 H, OCH3), 3.14–3.05 (m, 1 H,
NCH2
aCH), 2.89 (d, J= 11.0 Hz, 1 H, CCH(CH2)2CH2a),
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2.43–2.29 (m, 3 H, CHCO, CH2CH2CH2CHO), 2.05–1.85




1.75–1.65 (m, 1 H, CCHCH2CH2
a), 1.65–1.50 (m, 5 H,
CCHCH2CH2
b, CH2CH2CHO), 1.33 (dq, J= 12.7/4.0 Hz, 1
H, CCHCH2
bCH2) ppm;
13C NMR (100MHz, CD3OD/1 M
NaOD in D2O 6:1): δ= 183.0 (CO), 106.1 (OCHO), 59.7
(CH2(CH2)2CHO), 57.9 (CHCH2N), 54.7 (CCH(CH2)2CH2),
53.8 (OCH3), 46.2 (CHCO), 31.7 (CH2CHO), 29.3
(CCHCH2CH2), 25.7 (CCHCH2CH2), 22.3 (CH2CH2CHO)




According to GP2: Tricyclic imine 10a (30 mg, 0.20 mmol,
1 equiv), sodium triacetoxyborohydride (106 mg,
0.500 mmol, 2.5 equiv), acetic acid (25 mg, 0.42 mmol,
24 μL, 2.1 equiv), ethyl 1-(3,3-dimethoxypropyl)
piperidine-3-carboxylate rac-15e (104 mg, 0.400 mmol, 2
equiv) and FeCl3 ∙ 6H2O (303 mg, 1.12 mmol, 5.6 equiv).
The reaction was kept at 40 °C for 18 h. The crude product
was purified by FC and RP-MPLC. The product was
obtained as yellow oil (19 mg, 27%). IR (film) ~v= 2939,
2858, 2800, 1734, 1450, 1373, 1309, 1223, 1205, 1178,
1151, 1099, 1032 cm−1; 1H NMR (400MHz, CD2Cl2): δ=
4.08 (q, J= 7.1 Hz, 2 H, CH2CH3), 2.91 (d, J= 11.0 Hz, 1
H, OCCHCH2
aN,), 2.77–2.68 (m, 2 H, CHCH2CH2CH2
a,
CHN), 2.67 (d, J= 2.5 Hz, 2 H, CHNCH2CH), 2.49 (tt, J=
10.3/3.8 Hz, 1 H, OCCH), 2.45–2.38 (m, 2 H,
CHNCH2CH2), 2.37–2.28 (m, 2 H, CHN(CH2)2CH2), 2.11
(t, J= 10.4 Hz, 1 H, OCCHCH2bN), 1.95 (ddd, J= 10.8/
10.8/2.6 Hz, 1 H, CHCH2CH2CH2
b), 1.91–1.81 (m, 1 H,
CHCH2
aCH2), 1.78–1.63 (m, 3 H, CHCH2CH2
a, NCH
(CH2





b)2), 1.36 (s, 1 H,
CHNCH2CH), 1.33 (d, J= 8.6 Hz, 1 H, CCH2bC), 1.23 (t,
J= 7.1 Hz, 3 H, CH2CH3), 0.98 (s, 6 H, CCH3) ppm; 13C
NMR (100MHz, CD2Cl2) δ= 174.5 (CO), 60.5 (CH2CH3),
57.3 (CHN(CH2)2CH2), 56.1 (OCCHCH2N), 55.5
(CHNCH2CH2), 54.3 (CHCH2CH2CH2), 53.4 (NCH), 51.3
(CCH2C), 47.7 (CHNCH2CH), 45.6 (CHNCH2CH), 42.4
(OCCH), 39.6 (NCH(CH2)2), 36.0 (CCH3), 27.5
(CHCH2CH2), 26.5 (CHNCH2CH2), 25.5 (CCH3), 25.1
(CHCH2CH2), 14.4 (CH2CH3) ppm; HRESIMS m/z (pos):
349.2848 C21H37N2O2 (calcd. 349.2850).
rac-Ethyl 1-[3-(1,7-diphenyl-4-azatricyclo[3.3.1.02,7]nonan-
4-yl)propyl]piperidine-3-carboxylate rac-19b
According to GP2: Tricyclic imine 10b (27 mg, 0.10 mmol,
1 equiv), sodium triacetoxyborohydride (53 mg, 0.25 mmol,
2.5 equiv), acetic acid (13 mg, 0.21 mmol, 12 μL, 2.1
equiv), ethyl 1-(3,3-dimethoxypropyl)piperidine-3-carbox-
ylate rac-15e (52 mg, 0.20 mmol, 2 equiv) and FeCl3 ∙
6H2O (541 mg, 2.00 mmol, 20 equiv). The reaction was
kept at 40 °C for 12 h. The crude product was purified by
FC and RP-MPLC. The product was obtained as yellow oil
(11 mg, 23%). IR (film) ~v= 3056, 3024, 2935, 2854, 2804,
1730, 1603, 1495, 1444, 1367, 1309, 1178, 1151, 1030,
758, 698 cm−1; 1H NMR (500MHz, CD2Cl2): δ=
7.34–7.29 (m, 4 H, CCHCH), 7.29–7.24 (m, 4 H, CCHCH),
7.18 (tt, J= 7.1/1.4 Hz, 2 H, CCHCHCH), 4.09 (q, J=
7.1 Hz, 2 H, CH2CH3), 3.17 (d, J= 2.4 Hz, 2 H,
CHNCH2CH), 3.02 (p, J= 1.6 Hz, 1 H, CHN), 2.95 (d, J=
10.5 Hz, 1 H, OCCHCH2
aN), 2.73 (d, J= 10.9 Hz, 1 H,
CHCH2CH2CH2
a), 2.58 (dd, J= 7.3/7.3 Hz, 2 H,
CHNCH2CH2), 2.55 (s, 1 H, CCHC), 2.51 (tt, J= 10.3/
3.9 Hz, 1 H, OCCH), 2.44 (dt, J= 8.7/2.0 Hz, 1 H,
CCH2
aC), 2.41–2.36 (m, 2 H, CHN(CH2)2CH2,), 2.27 (d,
J= 13.1 Hz, 2 H, NCH(CH2a)2), 2.14 (t, J= 10.4 Hz, 1 H,
OCCHCH2
bN,), 2.11–2.05 (m, 3 H, CCH2
bC, NCH(CH2
b)2),
1.99 (ddd, J= 10.9/10.9/2.1 Hz, 1 H, CHCH2CH2CH2b),
1.92–1.85 (m, 1 H, CHCH2
aCH2), 1.74–1.67 (m, 1 H,
CHCH2CH2
a), 1.65 (p, J= 7.3 Hz, 2 H, NCH2CH2CH2N),
1.58–1.48 (m, 1 H, CHCH2CH2
b), 1.48–1.38 (m, 1 H,
CHCH2
bCH2), 1.23 (t, J= 7.1Hz, 3 H, CH2CH3) ppm; 13C
NMR (125MHz, CD2Cl2) δ= 174.5 (CO), 149.4 (CCHCH),
128.7 (CCHCH), 126.1 (CCHCHCH), 125.4 (CCHCH), 60.5
(CH2CH3), 57.2 (CHN(CH2)2CH2), 56.1 (OCCHCH2N), 55.6
(CHNCH2CH2), 54.3 (CHCH2CH2CH2), 53.6 (NCH), 49.9
(CHNCH2CH), 49.1 (CCH2C), 44.1 (CHNCH2CH), 42.5
(CCH2C), 42.4 (OCCH), 40.8 (NCH(CH2)2), 27.5
(CHCH2CH2), 26.6 (NCH2CH2CH2N), 25.1 (CHCH2CH2),




According to GP2: Tricyclic imine 10c (33 mg,
0.20 mmol, 1 equiv), sodium triacetoxyborohydride
(106 mg, 0.500 mmol, 2.5 equiv), acetic acid (25 mg,
0.42 mmol, 24 μL, 2.1 equiv), ethyl 1-(3,3-dimethox-
ypropyl)piperidine-3-carboxylate rac-15e (104 mg,
0.400 mmol, 2 equiv) and FeCl3 ∙ 6H2O (303 mg,
1.12 mmol, 5.6 equiv). The reaction was kept at 20 °C for
12 h. The crude product was purified by FC. The product
was obtained as yellow oil (19 mg, 26%). IR (film) ~v=
2942, 2864, 2804, 1732, 1450, 1371, 1311, 1209, 1180,
1153, 1099, 1032 cm−1; 1H NMR (500 MHz, CD2Cl2): δ
= 4.08 (q, J= 7.1 Hz, 2 H, OCH2CH3), 2.90 (d, J=
10.5 Hz, 1 H, OCCHCH2
aN), 2.74 (s, 2 H, CHNCH2CH),
2.70 (d, J= 10.9 Hz, 1 H, CHCH2CH2CH2a), 2.56–2.39
(m, 4 H, CHNCH2CH2, NCH, OCCH), 2.37–2.29 (m, 2
H, CHN(CH2)2CH2), 2.13 (t, J= 10.3 Hz, 1 H,
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OCCHCH2
bN), 1.97 (ddd, J= 10.6/10.6/2.2 Hz, 1 H,
CHCH2CH2CH2
b), 1.91–1.82 (m, 1 H, CHCH2
aCH2),
1.76 (d, J= 12.8 Hz, 2 H, NCH(CH2a)2), 1.72–1.65 (m, 1
H, CHCH2CH2
a), 1.61 (p, J= 7.3 Hz, 2 H,
NCH2CH2CH2), 1.56–1.36 (m, 6 H, CHCH2
bCH2,
CHCH2CH2
b, CCH2CH2C), 1.29–1.19 (m, 5 H, NCH
(CH2
b)2, CH2CH3), 1.10 (s, 6 H, CCH3), 0.88 (s, 1 H,
CHNCH2CH) ppm;
13C NMR (100 MHz, CD2Cl2) δ=
174.5 (CO), 60.5 (CH2CH3), 57.0 (CHN(CH2)2CH2),
56.1 (OCCHCH2N), 54.5 (CHNCH2CH2), 54.3
(CHCH2CH2CH2), 52.0 (NCH), 49.6 (CHNCH2CH), 46.1
(CHNCH2CH), 42.6 (OCCH), 41.9 (NCH(CH2)2), 40.8
(CCH2CH2C), 39.6 (CCH3), 27.8 (CCHCH2CH2), 26.6
(CCH3), 25.7 (CHNCH2CH2), 25.1 (CHCH2CH2), 14.5




According to GP2: Tricyclic imine 10d (29 mg,
0.10 mmol, 1 equiv), sodium triacetoxyborohydride
(53 mg, 0.25 mmol, 2.5 equiv), acetic acid (13 mg,
0.21 mmol, 12 μL, 2.1 equiv), ethyl 1-(3,3-dimethox-
ypropyl)piperidine-3-carboxylate rac-15e (52 mg,
0.20 mmol, 2 equiv) and FeCl3 ∙ 6H2O (151 mg,
0.560 mmol, 5.6 equiv). The reaction was kept at 20 °C for
12 h. The crude product was purified by FC and RP-MPLC.
The product was obtained as yellow oil (12 mg, 25%). IR
(film) ~v= 3055, 3022, 2943, 2868, 2804, 1730, 1601,
1495, 1470, 1444, 1369, 1309, 1178, 1151, 1032, 760,
700 cm−1; 1H NMR (400MHz, CD2Cl2): δ= 7.52–7.42
(m, 4 H, CCHCH), 7.40–7.30 (m, 4 H, CCHCH),
7.24–7.17 (m, 2 H, CCHCHCH), 4.07 (q, J= 7.1 Hz, 2 H,
OCH2), 2.87 (d, J= 11.3 Hz, 1 H, OCCHCH2aN), 2.82 (s,
1 H, NCH), 2.71 (d, J= 1.6 Hz, 2 H, CHNCH2CH),
2.66 (d, J= 11.5 Hz, 1 H, CHCH2CH2CH2a), 2.53–2.38
(m, 4 H, CHCH2NCH, OCCH, NCH(CH2
a)2), 2.38–2.25
(m, 4 H, NCH2CH2CH2N), 2.08 (t, J= 10.5 Hz, 1 H,
OCCHCH2





(m, 1 H, CHCH2CH2
a), 1.58–1.33 (m, 4 H, CHCH2
bCH2,
NCH2CH2CH2N, CHCH2CH2
b), 1.21 (t, J= 7.1 Hz, 3 H,
CH3) ppm;
13C NMR (100MHz, CD2Cl2) δ= 174.5 (CO),
149.9 (CH2CC), 128.6 (CCHCH), 126.5 (CCHCH), 125.8
(CCHCHCH.), 60.5 (OCH2), 57.2 (CHN(CH2)2CH2),
56.1 (OCCHCH2N), 54.3 (CHCH2CH2CH2), 54.1
(CHNCH2CH2), 51.7 (NCH), 47.3 (CCH2), 46.7
(CHNCH2CH), 44.9 (CHNCH2CH), 42.5 (CCH2CH2C),
42.4 (OCCH), 42.3 (NCH(CH2)2), 27.4 (CH2CH2CH), 26.0
(CHNCH2CH2), 25.1 (CHCH2CH2), 14.4 (CH3) ppm;




According to GP3: Tricyclic imine 10e (36 mg, 0.20 mmol,
1 equiv), sodium cyanoborohydride (66 mg, 1.0 mmol, 5
equiv), hydrochloric acid (73 mg, 2.0 mmol, 2.0 mL, 10
equiv), sodium triacetoxyborohydride (106 mg,
0.500 mmol, 2.5 equiv), acetic acid (25 mg, 0.42 mmol,
24 μL, 2.1 equiv), ethyl 1-(3,3-dimethoxypropyl)piperidine-
3-carboxylate rac-15e (104 mg, 0.400 mmol, 2 equiv) and
FeCl3 ∙ 6H2O (1.08 g, 4.00 mmol, 20 equiv). The reaction
was stirred at 40 °C for 12 h. The crude product was purified
by FC. The product was obtained as yellow oil (28 mg,
37%). IR (film) ~v= 2922, 2802, 1732, 1497, 1471, 1446,
1373, 1306, 1180, 1151, 1103, 1034, 862 cm−1; 1H NMR
(500MHz, CD2Cl2): δ= 4.08 (q, J= 7.1 Hz, 2 H,
CH2CH3), 2.96–2.84 (m, 3 H, CHNCH2CH, OCCHCH2
aN),
2.71 (d, J= 11.2 Hz, 1 H, CHCH2CH2CH2a), 2.61 (br s, 1
H, CHN), 2.56–2.45 (m, 3 H, CHNCH2CH2, OCCH), 2.33
(dd, J= 7.4/7.4 Hz, 2 H, CHN(CH2)2CH2), 2.11 (t, J=
10.5 Hz, 1 H, OCCHCH2
bN), 1.96 (ddd, J= 10.9/10.9/
2.4 Hz, CHCH2CH2CH2
b), 1.90–1.82 (m, 1 H,
CHCH2
aCH2), 1.73–1.65 (m, 1 H, CHCH2CH2
a), 1.64–1.47




a), 1.46–1.36 (m, 2 H, CHCH2
bCH2, CCH2CH2
b),




(t, J= 7.1 Hz, 3 H, CH2CH3), 1.10 (dd, J= 13.5/4.6 Hz, 2
H, CCH2
bCH2CH2
bC), 1.05 (s, 6 H, CCH3), 0.68 (s, 1 H,
CHNCH2CH) ppm;
13C NMR (125MHz, CD2Cl2) δ=
174.5 (CO), 60.5 (CH2CH3), 57.1 (CHN(CH2)2CH2),
56.1 (OCCHCH2N), 54.8 (CHNCH2CH2), 54.3
(CHCH2CH2CH2), 52.9 (NCH), 47.6 (CHNCH2CH), 46.3
(CHNCH2CH), 42.5 (OCCH), 40.8 (CCH2CH2CH2C), 36.8
(NCH(CH2)2), 31.0 (CCH3, CCH3), 27.5 (CCHCH2CH2),
26.4 (CHNCH2CH2), 25.1 (CHCH2CH2), 19.6 (CCH2CH2),




According to GP3: Tricyclic imine 10f (30 mg, 0.10 mmol,
1 equiv), sodium cyanoborohydride (33 mg, 0.50 mmol, 5
equiv), hydrochloric acid (36 mg, 1.0 mmol, 1.0 mL, 10
equiv), sodium triacetoxyborohydride (53 mg, 0.25 mmol,
2.5 equiv), acetic acid (13 mg, 0.21 mmol, 12 μL, 2.1
equiv), ethyl 1-(3,3-dimethoxypropyl)piperidine-3-carbox-
ylate rac-15e (52 mg, 0.20 mmol, 2 equiv) and FeCl3 ∙
6H2O (541 mg, 2.00 mmol, 20 equiv). The reaction was
stirred at 40 °C for 12 h. The crude product was purified by
FC and RP-MPLC. The product was obtained as colorless
viscous oil (17 mg, 34%). IR (film) ~v= 3057, 2926, 2852,
2802, 1730, 1597, 1495, 1444, 1369, 1306, 1180, 1151,
Medicinal Chemistry Research (2021) 30:586–609 597
1032, 758, 700 cm−1; 1H NMR (500MHz, CD2Cl2): δ=
7.52–7.47 (m, 4 H, CCHCH), 7.37–7.31 (m, 4 H, CCHCH),
7.19 (t, J= 7.3 Hz, 2 H, CCHCHCH), 4.06 (q, J= 7.2 Hz, 2
H, OCH2), 2.88 (s, 1 H, NCH), 2.81 (d, J= 11.0 Hz, 1 H,
OCCHCH2
aN), 2.63–2.53 (m, 3 H, NCH(CH2
a)2,
CHCH2CH2CH2
a), 2.50 (d, J= 2.1 Hz, 2 H, CHNCH2CH),
2.39 (tt, J= 10.4/3.8 Hz, 1 H, OCCH), 2.35 (s, 1 H,
CHCH2NCH), 2.22–2.11 (m, 4 H, CHN(CH2)2CH2,
CHNCH2CH2), 1.99 (t, J= 10.4 Hz, 1 H, OCCHCH2bN),





a), 1.65–1.37 (m, 8 H, CHCH2
bCH2,
CHCH2CH2, CCH2CH2
b, CCH2CH2CH2C), 1.37–1.32 (m,
2 H, CHNCH2CH2), 1.21 (t, J= 7.2 Hz, 3 H, CH3) ppm;
13C NMR (125MHz, CD2Cl2) δ= 174.5 (CO), 151.9
(CH2CC), 128.5 (CCHCH), 126.7 (CCHCH), 125.7
(CCHCHCH.), 60.5 (OCH2), 56.9 (CHN(CH2)2CH2), 56.0
(OCCHCH2N), 54.5 (CHNCH2CH2), 54.1
(CHCH2CH2CH2), 51.5 (NCH), 49.3 (CHNCH2CH), 43.7
(CCH2CH2CH2C), 42.4 (OCCH), 40.2 (CCH2), 39.1
(CHNCH2CH), 36.0 (NCH(CH2)2), 27.4 (CH2CH2CH),
26.2 (CHNCH2CH2), 25.0 (CHCH2CH2), 20.6 (CCH2CH2),




According to GP2: Tricyclic imine 10a (30 mg, 0.20 mmol,
1 equiv), sodium triacetoxyborohydride (106 mg,
0.500 mmol, 2.5 equiv), acetic acid (25 mg, 0.42 mmol,
24 μL, 2.1 equiv), ethyl 1-(4,4-dimethoxybutyl)piperidine-
3-carboxylate rac-15f (109 mg, 0.400 mmol, 2 equiv) and
FeCl3 ∙ 6H2O (303 mg, 1.12 mmol, 5.6 equiv). The reaction
was kept at 40 °C for 20 h. The crude product was purified
by FC. The product was obtained as viscous yellow oil
(32 mg, 44%). IR (film) ~v= 2937, 2858, 2802, 1732, 1660,
1450, 1373, 1309, 1180, 1151, 1093, 1032 cm−1; 1H NMR
(400MHz, CD2Cl2): δ= 4.08 (q, J= 7.1 Hz, 2 H,
CH2CH3), 2.95–2.83 (m, 2 H, OCCHCH2
aN, CHN), 2.76 (d,
J= 1.2 Hz, 2 H, CHNCH2CH), 2.72 ‒ 2.65 (m, 1 H,
CHCH2CH2CH2
a), 2.56–2.44 (m, 3 H, CHNCH2CH2,
OCCH), 2.35–2.25 (m, 2 H, CHN(CH2)3CH2), 2.10 (t, J=
10.6 Hz, 1 H, OCCHCH2
bN), 1.95 (ddd, J= 10.8/10.8/
2.6 Hz, 1 H, CHCH2CH2CH2
b), 1.91–1.78 (m, 3 H,
CHCH2
aCH2, NCH(CH2
a)2), 1.72–1.64 (m, 1 H,
CHCH2CH2
a), 1.59 (dd, J= 13.1/3.5 Hz, 2 H, NCH(CH2b)2),




aC, CCHC), 1.35 (d, J= 8.7 Hz,
1 H, CCH2
bC), 1.22 (t, J= 7.1 Hz, 3 H, CH2CH3), 1.00 (s, 6
H, CCH3) ppm;
13C NMR (100MHz, CD2Cl2) δ= 174.5
(CO), 60.5 (CH2CH3), 58.9 (CHN(CH2)3CH2), 56.9
(CHNCH2CH2), 56.0 (OCCHCH2N), 54.2 (CHCH2CH2CH2),
53.4 (NCH), 51.1 (CCH2C), 47.5 (CHNCH2CH), 45.1
(CHNCH2CH), 42.4 (OCCH), 38.8 (NCH(CH2)2), 36.0
(CCH3), 27.5 (CHCH2CH2), 26.1 (CHNCH2CH2CH2), 25.4
(CCH3), 25.1 (CHCH2CH2), 25.0 (CHNCH2CH2), 14.4




According to GP2: Tricyclic imine 10b (27 mg, 0.10 mmol,
1 equiv), sodium triacetoxyborohydride (53 mg, 0.25 mmol,
2.5 equiv), acetic acid (13 mg, 0.21 mmol, 12 μL, 2.1
equiv), ethyl 1-(4,4-dimethoxybutyl)piperidine-3-carbox-
ylate rac-15f (55 mg, 0.20 mmol, 2 equiv) and FeCl3 ∙ 6H2O
(151 mg, 0.560 mmol, 5.6 equiv). The reaction was kept at
40 °C for 20 h. The crude product was purified by FC and
RP-MPLC. The product was obtained as yellow oil (23 mg,
47%). IR (film) ~v= 3057, 3026, 2935, 2856, 2802, 1730,
1603, 1495, 1446, 1367, 1309, 1178, 1153, 1030, 758,
700 cm−1; 1H NMR (400MHz, CD2Cl2): δ= 7.35–7.24 (m,
8 H, CCHCH, CCHCH), 7.22–7.16 (m, 2 H, CCHCHCH),
4.09 (q, J= 7.1 Hz, 2 H, CH2CH3), 3.19 (d, J= 1.8 Hz, 2
H, CHNCH2CH), 3.07 (s, 1 H, CHN), 2.93 (d, J= 10.7 Hz,
1 H, OCCHCH2
aN), 2.72 (d, J= 11.1 Hz, 1 H,
CHCH2CH2CH2
a), 2.60 (t, J= 3.1 Hz, 2 H, CHNCH2CH2),
2.56 (s, 1 H, CCHC), 2.51 (tt, J= 10.3/3.9 Hz, 1 H, OCCH),
2.45 (dt, J= 8.8/2.3 Hz, 1 H, CCH2aC), 2.38–2.25 (m, 4 H,
CHN(CH2)3CH2, NCH(CH2




b)2), 1.97 (ddd, J= 10.8/
10.8/2.6 Hz, 1 H, CHCH2CH2CH2
b), 1.92–1.85 (m, 1 H,
CHCH2
aCH2), 1.74–1.65 (m, 1 H, CHCH2CH2
a), 1.60–1.37
(m, 6 H, CHCH2
bCH2, CHCH2CH2
b, NCH2CH2CH2CH2N),
1.23 (t, J= 7.1 Hz, 3 H, CH2CH3) ppm; 13C NMR
(100MHz, CD2Cl2) δ= 174.5 (CO), 149.2 (CCHCH), 128.7
(CCHCH), 126.2 (CCHCHCH), 125.4 (CCHCH), 60.5
(CH2CH3), 59.1 (CHN(CH2)3CH2), 57.3 (CHNCH2CH2),
56.0 (OCCHCH2N), 54.2 (CHCH2CH2CH2), 53.6 (NCH),
49.8 (CHNCH2CH), 48.9 (CCH2C), 44.0 (CHNCH2CH),
42.5 (CCH2C), 42.4 (OCCH), 40.6 (NCH(CH2)2), 27.5
(CHCH2CH2), 26.7 (CHNCH2CH2CH2), 25.1 (CHCH2CH2),
25.0 (CHNCH2CH2), 14.4 (CH2CH3) ppm; HRESIMS m/z
(pos): 487.3317 C32H43N2O2 (calcd. 487.3319).
rac-Ethyl 1-[4-(3,6-dimethyl-9-azatricyclo[4.3.1.03,7]decan-9-
yl)butyl]piperidine-3-carboxylate rac-19j
According to GP2: Tricyclic imine 10c (50 mg, 0.31 mmol,
1 equiv), sodium triacetoxyborohydride (162 mg,
0.766 mmol, 2.5 equiv), acetic acid (39 mg, 0.64 mmol,
37 μL, 2.1 equiv), ethyl 1-(4,4-dimethoxybutyl)piperidine-
3-carboxylate rac-15f (167 mg, 0.613 mmol, 2 equiv) and
FeCl3 ∙ 6H2O (464 mg, 1.72 mmol, 5.6 equiv). The reaction
was kept at 20 °C for 2 h. The crude product was purified by
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FC. The product was obtained as yellow oil (84 mg, 73%). IR
(film) ~v= 2941, 2864, 2802, 1734, 1468, 1452, 1371, 1311,
1178, 1153, 1101, 1034, 862 cm−1; 1H NMR (500MHz,
CD2Cl2): δ= 4.08 (q, J= 7.2 Hz, 2 H, OCH2CH3), 2.91
(d, J= 10.3 Hz, 1 H, OCCHCH2aN), 2.78‒2.63 (m, 3 H,
CHCH2CH2CH2
a, CHNCH2CH), 2.49 (tt, J= 10.4/3.8 Hz, 1
H, OCCH), 2.44 (br s, 1 H, NCH), 2.39 (t, J= 7.2 Hz, 2 H,
CHNCH2CH2), 2.34–2.27 (m, 2 H, CHN(CH2)3CH2), 2.09 (t,
J= 10.4 Hz, 1 H, OCCHCH2bN), 1.95 (dt, J= 10.9/2.4 Hz, 1
H, CHCH2CH2CH2
b), 1.91–1.83 (m, 1 H, CHCH2
aCH2),
1.78–1.64 (m, 3 H, CHCH2CH2
a, NCH(CH2
a)2), 1.58–1.33
(m, 10 H, CHCH2
bCH2, CHCH2CH2
b, NCH2CH2CH2CH2N,
CCH2CH2C), 1.28–1.18 (m, 5 H, NCH(CH2
b)2, CH2CH3),
1.09 (s, 6 H, CCH3), 0.85 (t, J= 2.3 Hz, 1 H, CHNCH2CH)
ppm; 13C NMR (125MHz, CD2Cl2) δ= 174.6 (CO), 60.5
(CH2CH3), 59.2 (CHN(CH2)3CH2), 56.4 (CHNCH2CH2),
56.0 (OCCHCH2N), 54.2 (CHCH2CH2CH2), 51.8 (NCH),
49.9 (CHNCH2CH), 46.2 (CHNCH2CH), 42.4 (NCH(CH2)2,
OCCH), 40.8 (CCH2CH2C), 39.7 (CCH3), 27.5
(CCHCH2CH2), 26.7 (CCH3), 26.6 (CHNCH2CH2CH2),
25.1 (CHNCH2CH2, CHCH2CH2), 14.4 (CH2CH3) ppm;




According to GP2: Tricyclic imine 10d (50 mg, 0.17 mmol,
1 equiv), sodium triacetoxyborohydride (92 mg, 0.44 mmol,
2.5 equiv), acetic acid (22 mg, 0.37 mmol, 21 μL, 2.1
equiv), ethyl 1-(4,4-dimethoxybutyl)piperidine-3-carbox-
ylate rac-15f (116 mg, 0.348 mmol, 2 equiv) and FeCl3 ∙
6H2O (263 mg, 0.974 mmol, 5.6 equiv). The reaction was
kept at 20 °C for 2 h. The crude product was purified by FC.
The product was obtained as brown oil (63 mg, 72%). IR
(film) ~v= 2939, 2804, 2360, 1730, 1601, 1495, 1444, 1369,
1309, 1178, 1151, 1032, 910, 760, 733, 700 cm−1; 1H NMR
(400MHz, CDCl3): δ= 7.50–7.40 (m, 4 H, CCHCH),
7.39–7.30 (m, 4 H, CCHCH), 7.21 (tt, J= 7.3/1.3 Hz, 2 H,
CCHCHCH), 4.11 (q, J= 7.1 Hz, 2 H, OCH2), 2.94 (d, J=
11.2 Hz, 1 H, OCCHCH2
aN), 2.87 (s, 1 H, NCH), 2.75
(d, J= 2.3 Hz, 2 H, CHNCH2CH), 2.71 (d, J= 11.1 Hz, 1
H, CHCH2CH2CH2
a), 2.61–2.46 (m, 3 H, OCCH, NCH
(CH2
a)2), 2.41 (s, 1 H, CHCH2NCH), 2.33 (t, J= 7.1 Hz, 2
H, CHNCH2CH2), 2.30–2.24 (m, 2 H, CHN(CH2)3CH2),










bC), 1.73–1.64 (m, 1 H, CHCH2CH2
a),
1.60–1.51 (m, 1 H, CHCH2CH2
b), 1.51–1.34 (m, 5 H,
CHCH2
bCH2, NCH2CH2CH2CH2N), 1.23 (t, J= 7.1 Hz, 3
H, CH3) ppm;
13C NMR (100MHz, CDCl3) δ= 174.4
(CO), 149.0 (CH2CC), 128.5 (CCHCH), 126.1 (CCHCH),
125.7 (CCHCHCH.), 60.4 (OCH2), 58.8 (CHN(CH2)3CH2),
55.6 (OCCHCH2N, CHNCH2CH2), 53.8 (CHCH2CH2CH2),
51.4 (NCH), 46.9 (CCH2), 46.2 (CHNCH2CH), 44.6
(CHNCH2CH), 42.2 (CCH2CH2C), 42.0 (OCCH), 41.8
(NCH(CH2)2), 27.2 (CH2CH2CH), 25.8 (CHN(CH2)2CH2),
24.7 (CHNCH2CH2), 24.7 (CHCH2CH2), 14.3 (CH3) ppm;




According to GP3: Tricyclic imine 10e (32 mg, 0.18 mmol,
1 equiv), sodium cyanoborohydride (30 mg, 0.45 mmol, 2.5
equiv), hydrochloric acid (33 mg, 0.90 mmol, 0.9 mL, 5
equiv), sodium triacetoxyborohydride (95 mg, 0.45 mmol,
2.5 equiv), acetic acid (23 mg, 0.38 mmol, 22 μL, 2.1
equiv), ethyl 1-(4,4-dimethoxybutyl)piperidine-3-carbox-
ylate rac-15f (98 mg, 0.36 mmol, 2 equiv) and FeCl3 ∙ 6H2O
(272 mg, 1.01 mmol, 5.6 equiv). Deviating from GP3 only
2.5 equiv NaCNBH3 and 5 equiv HCl were used. The
reaction was kept at 20 °C for 2 h. The crude product was
purified by FC. The product was obtained as yellow oil
(25 mg, 36%). IR (film) ~v= 2924, 2800, 1734, 1497, 1452,
1373, 1304, 1178, 1151, 1103, 1034, 862 cm−1; 1H NMR
(400MHz, CDCl3): δ= 4.11 (q, J= 7.1 Hz, 2 H, CH2CH3),
2.97 (dd, J= 11.2/2.9 Hz, 1 H, OCCHCH2aN), 2.91 (d, J=
1.7 Hz, 2 H, CHNCH2CH), 2.76 (d, J= 11.2 Hz, 1 H,
CHCH2CH2CH2
a), 2.69 (br s, 1 H, CHN), 2.58–2.48 (m, 3 H,
CHNCH2CH2, OCCH), 2.37–2.28 (m, 2 H, CHN(CH2)3CH2),
2.08 (t, J= 10.8 Hz, 1 H, OCCHCH2bN), 1.98–1.87 (m, 2
H, CHCH2
aCH2, CHCH2CH2CH2
b), 1.70 (dp, J= 13.4/
3.7 Hz, 1 H, CHCH2CH2









aC), 1.23 (t, J= 7.1 Hz, 3 H, CH2CH3), 1.10
(dd, J= 13.4/4.7 Hz, 2 H, CCH2bCH2CH2bC), 1.05 (s, 6 H,
CCH3), 0.68 (t, J= 2.3 Hz, 1 H, CHNCH2CH) ppm; 13C
NMR (100MHz, CDCl3) δ= 174.4 (CO), 60.4 (CH2CH3),
58.9 (CHN(CH2)3CH2), 56.2 (CHNCH2CH2), 55.6
(OCCHCH2N), 53.9 (CHCH2CH2CH2), 52.3 (NCH), 47.3
(CHNCH2CH), 45.7 (CHNCH2CH), 42.1 (OCCH), 40.5
(CCH2CH2CH2C), 36.1 (NCH(CH2)2), 30.9 (CCH3), 30.7
(CCH3), 27.2 (CCHCH2CH2), 26.3 (CHNCH2CH2), 24.8
(CHN(CH2)2CH2, CHCH2CH2), 19.2 (CCH2CH2), 14.3




According to GP3: Tricyclic imine 10f (30 mg,
0.10 mmol, 1 equiv), sodium cyanoborohydride (33 mg,
0.50 mmol, 5 equiv), hydrochloric acid (36 mg, 1.0 mmol,
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1.0 mL, 10 equiv), sodium triacetoxyborohydride (53 mg,
0.25 mmol, 2.5 equiv), acetic acid (13 mg, 0.21 mmol,
12 μL, 2.1 equiv), ethyl 1-(4,4-dimethoxybutyl)piper-
idine-3-carboxylate rac-15f (55 mg, 0.20 mmol, 2 equiv)
and FeCl3 ∙ 6H2O (151 mg, 0.560 mmol, 5.6 equiv). The
reaction was stirred at 40 °C for 12 h. The crude product
was purified by FC and RP-MPLC. The product was
obtained as colorless oil (18 mg, 35%). IR (film) ~v=
3055, 2933, 2854, 2802, 1730, 1597, 1495, 1444, 1369,
1304, 1178, 1151, 1031, 758, 700 cm−1; 1H NMR
(400 MHz, CD2Cl2): δ= 7.50 (d, J= 8.2 Hz, 4 H,
CCHCH), 7.41–7.30 (m, 4 H, CCHCH), 7.19 (t, J=
7.3 Hz, 2 H, CCHCHCH), 4.07 (q, J= 7.1 Hz, 2 H,
OCH2), 2.89–2.85 (m, 1 H, NCH), 2.82 (d, J= 10.2 Hz, 1
H, OCCHCH2
aN), 2.60 (d, J= 11.0 Hz, 1 H,
CHCH2CH2CH2
a), 2.56 (dd, J= 13.0/3.0 Hz, 2 H, NCH
(CH2
a)2), 2.49 (d, J= 2.4 Hz, 2 H, CHNCH2CH), 2.44 (tt,
J= 10.4/3.8 Hz, 1 H, OCCH), 2.35 (s, 1 H,
CHCH2NCH), 2.21–2.10 (m, 4 H, CHN(CH2)3CH2,
CHNCH2CH2), 2.01 (t, J= 10.3 Hz, 1 H, OCCHCH2bN),









(m, 2 H, CHNCH2CH2), 1.25–1.12 (m, 5 H, CH3, CHN
(CH2)2CH2) ppm;
13C NMR (100 MHz, CD2Cl2) δ=
174.5 (CO), 152.0 (CH2CC), 128.5 (CCHCH), 126.7
(CCHCH), 125.6 (CCHCHCH), 60.5 (OCH2), 59.0 (CHN
(CH2)3CH2), 56.3 (CHNCH2CH2), 56.0 (OCCHCH2N),
54.1 (CHCH2CH2CH2), 51.5 (NCH), 49.3 (CHNCH2CH),
43.8 (CCH2CH2CH2C), 42.4 (OCCH), 40.2 (CCH2), 39.1
(CHNCH2CH), 36.0 (NCH(CH2)2), 27.5 (CH2CH2CH),
26.8 (CHN(CH2)2CH2), 25.1 (CHCH2CH2), 24.9
(CHNCH2CH2), 20.6 (CCH2CH2), 14.4 (CH3) ppm;




The [3H]GABA uptake assays were performed as pre-
viously described with intact HEK293 cells stably expres-
sing mGAT1, mGAT2, mGAT3, mGAT4 in a 96-well plate
format [55].
MS binding assays
For the MS binding assays mGAT1 membrane preparations,
obtained from a stable HEK293 cell line, and NO711 as
native MS marker were employed in competitive binding
experiments as described earlier [56].
Results and discussion
Synthesis
As direct precursors for the preparation of the target com-
pounds rac-11 their carboxylic acid esters rac-19 should be
employed. Their synthesis should be accomplished by
linking of the tricyclic amines 14 with suitable N-substituted
nipecotic acid derivatives via reductive amination (Fig. 4).
Accordingly, besides the tricyclic amines 14, which should
be accessible from the tricyclic imines 10 by reduction,
nipecotic acid derivatives carrying N-alkyl substituents with
an aldehyde function at the terminal position of the N-alkyl
chain were needed. These nipecotic acid derivatives with N-
alkyl chains of different lengths between the amino nitrogen
and the terminal aldehyde function, rac-12 and rac-13,
should be generated from suitable precursors, rac-15, in
which the aldehyde function is present in masked form, for
instance as alcohol or acetal group.
Preparation of the aldehyde precursors rac-15a–f and
generation of the aldehydes rac-12–13
The required nipecotic acid derivatives with an N-alkyl
residue with a terminal alcohol or acetal function,
Fig. 4 Retrosynthetic analysis of the targeted N-substituted nipecotic
acid derivatives rac-11
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rac-15a–f, were obtained by N-alkylation of racemic ethyl
nipecotate rac-16 with ω-hydroxy and ω-dimethoxy sub-
stituted n-propyl- and n-butlyhalides 17a–b and 17e–f and
the ω-(1,3-dioxolane-2-yl) substituted ethyl- and n-pro-
pylhalides 17c–d, respectively, in good to excellent yields
(Table 1, entries 1–6). The synthesis of alcohol rac-15a
was performed according to a procedure described by
Dhar et al. [39], which method was also used for the
construction of rac-15b–f. As besides the aldehyde pre-
cursors rac-15a–f also the corresponding free carboxylic
acids rac-18a–f should be evaluated for their inhibitory
potency at mGAT1–mGAT4 the later were synthesized as
well. This was accomplished by treating rac-15a–f with
Ba(OH)2 ∙ 8 H2O in analogy to a literature procedure [33],
which led to rac-18a–f in moderate to excellent yields
(43–92%, Table 1, entries 1–6).
With the aldehyde precursors rac-15a–f in hand, the
synthesis of the aldehydes rac-12–13 was studied.
Attempts to access the aldehydes rac-12–13 by oxidation
of the alcohols rac-15a–b showed, that even using mild
oxidation conditions, e.g. Swern-, Parikh-Doering or
Dess-Martin periodinane oxidation, the desired aldehydes
were not formed or only in traces. As, in addition, the
starting material had been completely consumed and a
multitude of side products appeared, this approach was
dismissed. Instead attempts to deprotect the acetals rac-
Table 1 Synthesis of the nipecotic acid derived aldehyde precursors rac-15a–f and their hydrolysis to the carboxylic acids rac-18a–f
Reagents and conditions: (a) K2CO3, NaI, neat, acetone or 1,4-dioxane; (b) Ba(OH)2 ∙ 8 H2O, MeOH/H2O; (c) various conditions tested,
for rac-15e-f: FeCl3 ∙ 6 H2O, CH2Cl2
aSynthesis according to literature [39]
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15c–f were undertaken. In this regard, only reaction con-
ditions that should allow to deprotect the acetals without
affecting the ester function were taken into account.
Although several deprotection protocols were tested (I2,
acetone [57]; TMSOTf, 2,6-lutidine, CH2Cl2 [58]; pyr-
idinium p-toluenesulfonate, THF/H2O [59]; FeCl3 ∙ 6 H2O,
CH2Cl2 [60]; HCl, MeCN/H2O [61]), the cyclic acetals
rac-15c–d proofed to be too stable and showed only
marginal or no aldehyde formation. In contrast, the
dimethyl acetals rac-15e–f were easily deprotected by
treatment with FeCl3 ∙ 6 H2O in CH2Cl2 according to a
procedure of Sen et al. Analysis of the crude product from
the cleavage reaction of dimethyl acetal rac-15f directly
after aqueous workup by 1H NMR spectroscopy showed
predominant formation of aldehyde 13 (n= 1) and only
low amounts of remaining dimethyl acetal rac-15f.
However, the crude aldehyde rac-13 was contaminated
with unknown side products, resulting from decomposi-
tion most likely, which in addition to the dimethyl acetal
rac-15f could not be separated from the desired compound
rac-13. A similar situation was observed when the
deprotection of dimethyl acetal rac-15e to aldehyde rac-12
was attempted. In consequence, the crude aldehydes rac-
12–13 should be directly used for the subsequent reductive
amination without prior chromatographic purification and
without any delay.
Reduction of the imines 10a–f and synthesis of the target
compounds rac-11a–m
The amines 14a–f, required for the reductive amination of
rac-12 and rac-13, were synthesized by reduction of the






Entry Imine R1 m Acetal n Ester Yield Acid Yield
1 10a Me 0 rac-15e 0 rac-19a 27 rac-11a 87
2 10b Ph 0 rac-15e 0 rac-19b 23 rac-11b 91
3 10c Me 1 rac-15e 0 rac-19c 26 rac-11c 70
4 10d Ph 1 rac-15e 0 rac-19d 25 rac-11d 84
5 10e Me 2 rac-15e 0 rac-19e 37 rac-11e 81
6 10f Ph 2 rac-15e 0 rac-19f 34 rac-11f 73
7 10a Me 0 rac-15f 1 rac-19g 44 rac-11g 77
8 10b Ph 0 rac-15f 1 rac-19h 47 rac-11h 98
9 10c Me 1 rac-15f 1 rac-19j 73 rac-11j 97
10 10d Ph 1 rac-15f 1 rac-19k 72 rac-11k 65
11 10e Me 2 rac-15f 1 rac-19l 36 rac-11l 96
12 10f Ph 2 rac-15f 1 rac-19m 35 rac-11m 53
Reagents and conditions: (a) FeCl3 ∙ 6 H2O, CH2Cl2; (b) Reduction of 10a–d: NaBH(OAc)3, AcOH, CH2Cl2; (c) Reduction of 10e–f: NaBH3CN,
HCl, MeOH; (d) NaBH(OAc)3, AcOH, CH2Cl2; (e) BaOH2 ∙ 8 H2O, MeOH/H2O
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tricyclic imines 10a–f. The use of NaBH3CN under acidic
conditions seemed well suited for this purpose as it had
been successfully applied for the reduction of related tri-
cyclic imines with an 2-azabicyclo[2.2.2]octane scaffold
[50]. Indeed, when imines 10a–f were treated with
NaBH3CN and HCl in methanol the corresponding amines
14a–f were formed. Unfortunately, amines 14a–b (bridge
size m= 0) were found to be instable and to decompose
quickly, whereas amines 14c–f did not show such a beha-
vior. Hence, in addition to the aldehydes rac-12–13, it
seemed best to use also amines 14a–f directly after their
formation without prior purification and isolation.
Considering that both, the aldehydes rac-12–13 and
amines 14a–f had appeared to be labile to some extent, we
intended to generate and directly subject them to the next
reaction step, the reductive amination to give the respective
esters rac-19. Thus, for the overall reaction sequence first
acetals rac-15e–f should be cleaved by treatment with FeCl3
∙ 6 H2O in CH2Cl2. Then the respective aldehyde should be
added to a mixture of imine and reducing agent, which was
premixed to mediate imine reduction and to allow sub-
sequent reductive amination of the aldehyde function of
rac-12 or rac-13 with the formed amine. When in a test
reaction aldehyde 13 was added to a mixture of an imine,
structurally similar to imine 10c but with one of the methyl
residues substituted by hydrogen (for a depiction of the
structure see compound rac-14a in [49]), and NaBH3CN,
that had proven well suited for the reduction of the imines
10 to the corresponding amines 14, besides the reductive
amination product also the alcohol rac-15b resulting from
the reduction of aldehyde rac-13 was obtained. However,
when the mild reducing agent NaBH(OAc)3 [62, 63] in
combination with acetic acid was used instead of NaBH3CN
no such unfavorable reaction occurred. Thus, starting from
dimethyl acetal rac-15f and the imines 10a–d the esters rac-
19g–k were obtained in moderate to good yields (Table 2,
entries 7–10). This method could also successfully be
applied to the reductive coupling of dimethyl acetal rac-15e
—via the corresponding aldehyde rac-12—with the imines
10a–d to give the desired esters rac-19a–d. However, in
these cases the yields were poor (Table 2, entries 1–4),
which is likely to be attributed to the instability of the
intermediate aldehyde rac-12 and its propensity to undergo
a retro-Michael addition leading to further side reactions.
Unfortunately, the reaction of imines 10e–f with in situ
generated aldehydes rac-12 and rac-13 did not lead to the
desired products, the nipecotic acid esters rac-19e–f and
rac-19l–m under the aforementioned reaction conditions.
Actually, despite treatment with NaBH(OAc)3 imines 10e–f
remained unchanged, indicating that they are less reactive than
compounds 10a–d. This is likely to be due to a more severe
shielding of the imine function by the adjacent R1 groups as a
result of the larger “upper” bridge (m= 2) in 10e–f as it was
claimed before in cycloaddition reactions performed with these
compounds [51]. To overcome this problem the aforemen-
tioned procedure was changed as follows: Instead of NaBH
(OAc)3 NaBH3CN was employed for the reduction of imines
10e–f to the amines 14e–f. Then, when the conversion to the
amines 14e–f had gone to completion according to TLC,
excess reducing agent was removed by basic-aqueous workup
and the crude amines were reacted with NaBH(OAc)3 and the
aldehydes rac-12–13 in analogy to the original procedure.
That way, the remaining esters rac-19e–f and rac-19l–m could
finally be obtained in yields of 34–37% (Table 2, entries 5–6
and 11–12). Basic hydrolysis of the esters rac-19a–m with Ba
(OH)2 ∙ 8 H2O according to a literature procedure [33] pro-
vided finally the desired carboxylic acids rac-11a–m in
moderate to excellent yields (53–98%).
Biological evaluation
For the evaluation of the inhibitory potencies of the nipe-
cotic acid derivatives rac-11a–m exhibiting a free car-
boxylic acid function and a fully established lipophilic
domain, as well as of rac-18a–f possessing only small N-
substituents and their corresponding esters rac-15a–f and
rac-19a–m at the different GAT subtypes
mGAT1–mGAT4 a standardized [3H]GABA uptake assay
was used [55]. HEK293 cell lines, each stably expressing
one individual subtype of the GATs, represent the basis of
this assay. Additionally, with a MS Binding Assay the
binding affinities towards mGAT1 were determined using
NO711 as native MS marker. If the tested compounds did
not reduce the [3H]GABA uptake or NO711 marker
binding significantly below 50% in preliminary experi-
ments at a concentration of 100 µM, which corresponds to
a pIC50 of ≤ 4.0 and a pKi of ≤ 4.0 respectively, only
percent values of the remaining [3H]GABA uptake or
NO711 marker binding are given. In case of a significant
reduction of the [3H]GABA uptake or NO711 marker
binding below 50% at an inhibitor concentration of
100 µM, the inhibitory potency (pIC50) and the binding
affinity (pKi), respectively, were determined in a single
experiment performed in triplicates.
As Tiagabine (6), NO711 (7), (S)-SNAP-5114 (8), or
Deramciclane (rac-9) represent prototypic GAT inhibi-
tors, they provide important reference values for the
estimation of the biological activities of the newly syn-
thesized and tested compounds described in this paper,
despite the marked differences in their chemical struc-
tures. When considering the values of these reference
compounds (see Fig. 2), it must be noted that these were
partially obtained for enantiomerically pure [Tiagabine,
(S)-SNAP-5114] or achiral (NO711) GAT inhibitors,
whereas the substances displayed in this work are race-
mic mixtures.
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The initially tested nipecotic acid esters rac-15a–f, that
had been synthesized to serve as synthetic intermediates for
the introduction of the tricyclic cage unit, and the corre-
sponding carboxylic acids rac-18a–f displayed only very
weak to negligible inhibitory potency and affinity. Only the
dimethoxy substituted nipecotic acid derivatives rac-18e
and rac-18f showed weak inhibitory potency at mGAT1 the
remaining [3H]GABA uptake amounting to 50% and 46%,
respectively, at a test compound concentration of 100 µM.
In addition, these compounds displayed inhibitory potency
at mGAT3 and mGAT4, though this was even lower than
that at mGAT1 with values for the remaining [3H]GABA
uptake in the range of 61–75% (Table 3, entries 10 and 12).
Due to their structural similarity it seemed appropriate to
compare the test results for the synthesized carboxylic acids
rac-11a–m and carboxylic acid esters rac-19a–m exhibit-
ing a tricyclic residue as lipophilic domain among each
other as this should provide insight on the influence of the
spacer length (n), the bridge size (m) and the residues (R) on
the biological activity. The comparison of test results of
carboxylic acids of identical structure varying only in their
spacer lengths (n= 0 or n= 1) among each other showed
no significant impact of the spacer length on the biological
activity for most structures. Only for the two nipecotic acid
derivatives rac-11g and rac-11k with a butyl spacer
improved inhibitory potencies were observed compared to
their analogs with a propyl spacer rac-11a and rac-11d. For
compound rac-11g a pIC50 of 4.25 at mGAT1 was deter-
mined, whereas the structurally related carboxylic acid rac-
11a with a propyl spacer could only reduce the [3H]GABA
uptake to 66%. Even more pronounced was the effect for
carboxylic acid rac-11k for which a pIC50 of 4.40 at
mGAT1 and a remaining [3H]GABA uptake of 45% at
mGAT2 was found. The corresponding nipecotic acid
derivate rac-11d with a propyl spacer merely reduced the
[3H]GABA uptake to 66% at mGAT1 and to 79%
at mGAT2.
A comparative analysis of the biological activity of
carboxylic acid esters rac-19a–m among each other to
study the influence of the spacer length led to diverging
results. For some esters of otherwise identical structure the
variation of the spacer length did not seem to affect the
results of the biological testing (compare: rac-19a and rac-
19g; rac-19e and rac-19l). However, most nipecotic acid
ester derivatives showed differences in the biological
activity at the different GAT subtypes when the spacer
length was altered. The carboxylic ester rac-19b substituted
with phenyl residues and equipped with a methylene bridge
(m= 0) and a propyl spacer (n= 0) exhibited higher inhi-
bitory potencies at mGAT2 and mGAT3 with pIC50 values
of 4.53 and 4.43, respectively, compared to its analog rac-
19h with a butyl spacer. Yet this analog rac-19h displayed a
higher inhibitory potency at mGAT4 with a pIC50 value of
4.89, whereas the potencies at mGAT1 were almost iden-
tical. Nipecotic acid ester derivative rac-19c with a C3-
spacer reached lower remaining [3H]GABA uptake with
values ranging from 50 to 60% at mGAT2–mGAT4 as
compared to its structural analog rac-19j with a C4-spacer.
For the phenyl substituted ester rac-19k with a butyl spacer
(n= 1) and a C2-bridge (m= 1) at mGAT1–mGAT3 inhi-
bitory potencies with pIC50 values ranging from 4.60 to
4.65 were observed, whereas the related ester rac-19d with
a propyl spacer proofed to be less biologically active at
mGAT1–mGAT3 and to have an identical activity at
mGAT4. Finally, compound rac-19f displaying phenyl
residues, a C3-bridge (m= 2) and a propyl spacer (n= 0)
had a considerably higher activity at mGAT2 and mGAT3
with pIC50 values of 4.28 and 4.97, respectively, but also a
lower one at mGAT4 as compared to the analogous ester
rac-19m with a butyl spacer, who had pIC50 of 4.33 at
mGAT4. Unfortunately, these results did not indicate a
universal trend for the inhibitory potency at
mGAT1–mGAT4 when the spacer length was altered.
Further analysis of the biological activity of carboxylic
acids rac-11a–m by comparing structures deviating only in
their attached residues R1, being either methyl or phenyl
residues, showed that for most of the carboxylic acids the
residue had a very small to negligible effect on the inhibi-
tory potency at mGAT1–mGAT4 (compare rac-11a and
rac-11b; rac-11c and rac-11d; rac-11e and rac-11f; rac-11l
and rac-11m). Exceptions are the methyl-substituted nipe-
cotic acid derivative rac-11g with a butyl spacer (n= 1) and
a methylene bridge (m= 0), which had an improved inhi-
bitory potency at mGAT1 with a pIC50 of 4.25 as compared
to its phenyl substituted analog rac-11h, and the phenyl
substituted nipecotic acid derivative rac-11k with a butyl
spacer (n= 1) and a C2-bridge (m= 1), that had a higher
biological activity at mGAT1 and mGAT2 with a pIC50 of
4.40 and a remaining [3H]GABA uptake of 45%, respec-
tively, as compared to its related methyl-substituted car-
boxylic acid rac-11j.
When taking a look at the carboxylic acid esters rac-
19a–m it became evident that almost always the phenyl
substituted esters had higher inhibitory potencies at
mGAT1–mGAT4 than their otherwise identical methyl-
substituted analogs. This observation is nicely highlighted
by ester rac-19k with pIC50 values in a range of 4.60–4.65
at mGAT1–mGAT4, which are in strong contrast to the
biological results obtained for the related, basically inactive
methyl-substituted ester rac-19j. Obviously, the aromatic
phenyl residue in the nipecotic acid ester derived GAT
inhibitors seems to be necessary as structural element to
achieve a reasonable activity at all GAT subtypes.
The examination of the influence of the bridge size (m)
on the biological activity of the carboxylic acids rac-11a–m
at mGAT1–mGAT4 led to contradictory results. For the
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methyl-substituted nipecotic acid derivatives rac-11a, rac-
11c, and rac-11e with a propyl spacer (n= 0) no significant
effect of the bridge size on the inhibitory potencies at
mGAT1–mGAT4 could be observed. Also, the methyl-
substituted carboxylic acids rac-11g, rac-11j, and rac-11l
with a butyl spacer (n= 1) showed similar biological
activities at mGAT2–mGAT4 despite their varying bridge
size (m= 0–2) and only at mGAT1 a preference for the
carboxylic acid rac-11g with the smallest bridge size (m=
0), for which a pIC50 of 4.25 was found, could be noticed.
The comparison of the phenyl substituted carboxylic acids
rac-11b, rac-11d, and rac-11f with a propyl spacer (n= 0)
among each other indicated a preference for structures with
smaller bridge sizes with regard to biological activity at
mGAT1 and mGAT3 as the remaining [3H]GABA uptake
declined from 82 to 52% at mGAT1 and from 90 to 67% at
mGAT3 with decreasing bridge size. For these structures at
mGAT4 no influence of the bridge size on the biological
activity was observed and at mGAT2 only a weak pre-
ference for carboxylic acid rac-11f with a C3-bridge was
recognized. The comparative analysis of the phenyl sub-
stituted carboxylic acids rac-11h, rac-11k, and rac-11m
with a butyl spacer (n= 1), in contrast, showed a preference
for the medium-sized bridge (m= 1) for the biological
activity at mGAT1–mGAT3, as the best inhibitory poten-
cies with a pIC50 value of 4.40 at mGAT1 and remaining
[3H]GABA uptakes of 45–58% at mGAT2–mGAT3 were
determined for carboxylic acid rac-11k.
In addition, the influence of the bridge size (m) on the
biological activity was studied for the carboxylic acid esters
rac-19a–m. When the esters rac-19a, rac-19c, and rac-19e,
all equipped with methyl residues and a propyl spacer (n=
Table 3 Binding affinities and inhibitory potencies of nipecotic acid derivatives rac-15a–f and rac-18a–f
Entry Compound R2---------R3 n R4 pK i [a] pIC50 
[a]
mGAT1 mGAT1 mGAT2 mGAT3 mGAT4
1 rac-15a OH H 0 Et 91% 113% 89% 110% 99% 
2 rac-18a OH H 0 H 82% 67% 82% 81% 87% 
3 rac-15b OH H 1 Et 91% 111% 97% 103% 89% 
4 rac-18b OH H 1 H 96% 87% 93% 80% 96% 
5 rac-15c OCH2CH2O 0 Et 82% 104% 72% 92% 96% 
6 rac-18c OCH2CH2O 0 H 104% 71% 76% 70% 83% 
7 rac-15d OCH2CH2O 1 Et 86% 95% 88% 103% 85% 
8 rac-18d OCH2CH2O 1 H 103% 87% 92% 81% 89% 
9 rac-15e OMe OMe 0 Et 90% 93% 82% 106% 96% 
10 rac-18e OMe OMe 0 H 98% 50% 89% 61% 69% 
11 rac-15f OMe OMe 1 Et 87% 100% 89% 89% 100% 
12 rac-18f OMe OMe 1 H 97% 46% 97% 74% 75% 
aAll values were determined in one experiment performed in triplicate. The results of the MS binding assay are given as pKi, the results of the
[3H]GABA uptake assay as pIC50. Percent values indicate remaining specific NO711 binding or remaining [
3H]GABA uptake, respectively,
in presence of 100 µM test compound
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Table 4 Nipecotic acid derivatives possessing various tricyclic amines as substituents and their binding affinities and inhibitory potencies
Entry Compound R1 m n R4 pKi [a] pIC50 [a]
      mGAT1 mGAT1 mGAT2 mGAT3 mGAT4 
1 rac-19a Me 0 0 Et 95% 66% 61% 81% 69% 
2 rac-11a Me 0 0 H 82% 66% 78% 73% 81% 
3 rac-19b Ph 0 0 Et 4.62 4.32 4.53 4.46 4.59 
4 rac-11b Ph 0 0 H 68% 52% 79% 67% 68% 
5 rac-19c Me 1 0 Et 72% 86% 50% 60% 54% 
6 rac-11c Me 1 0 H 76% 50% 83% 75% 77% 
7 rac-19d Ph 1 0 Et 60% 4.37 58% 4.29 4.65 
8 rac-11d Ph 1 0 H 104% 66% 79% 79% 69% 
9 rac-19e Me 2 0 Et 89% 69% 76% 77% 89% 
10 rac-11e Me 2 0 H 88% 62% 72% 74% 87% 
11 rac-19f Ph 2 0 Et 78% 4.14 4.28 4.97 62% 
12 rac-11f Ph 2 0 H 98% 83% 57% 90% 71% 
13 rac-19g Me 0 1 Et 95% 59% 60% 77% 62% 
14 rac-11g Me 0 1 H 84% 4.25 80% 61% 71% 
15 rac-19h Ph 0 1 Et 81% 4.35 4.00 4.13 4.89 
16 rac-11h Ph 0 1 H 82% 67% 79% 77% 80% 
17 rac-19j Me 1 1 Et 106% 88% 81% 90% 86% 
18 rac-11j Me 1 1 H 84% 74% 102% 71% 96% 
19 rac-19k Ph 1 1 Et 84% 4.60 4.61 4.65 4.64 
20 rac-11k Ph 1 1 H 71% 4.40 45% 58% 83% 
21 rac-19l Me 2 1 Et 101% 83% 73% 86% 74% 
22 rac-11l Me 2 1 H 89% 78% 85% 79% 86% 
23 rac-19m Ph 2 1 Et 72% 4.18 59% 53% 4.33 
24 rac-11m Ph 2 1 H 104% 83% 76% 105% 76% 
aAll values were determined in one experiment performed in triplicate. The results of the MS binding assay are given as pKi, the results of the [
3H]
GABA uptake assay as pIC50. Percent values indicate remaining specific NO711 binding or remaining [
3H]GABA uptake, respectively, in presence
of 100 µM test compound
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0), were compared among each other, only for the inhibitory
potency at mGAT4 the bridge size seemed to be important
to some extent. Here ester rac-19c with a medium-sized C2-
bridge (m= 1) reducing the remaining [3H]GABA uptake to
54% at a test compound concentration of 100 µM proofed to
be best. Also, the biological activity of the methyl-
substituted esters rac-19g, rac-19j, and rac-19l with a
butyl spacer (n= 1) at mGAT2–mGAT4 appeared to be
rather unaffected by the bridge size of these compounds.
Solely, according to the results of the inhibitory potencies at
mGAT1, a methylene bridge (m= 0) mediates a slightly
higher potency at this GAT subtype (see ester rac-19g). The
comparative analysis of the test results of the phenyl sub-
stituted esters rac-19b, rac-19d, and rac-19f with a C3-
spacer (n= 0) showed, that ester rac-19f with the largest
bridge size (m= 2) turned out best to address mGAT3, with
a pIC50 value of 4.97, whereas, in order to address mGAT2,
ester rac-19b with the smallest bridge size (m= 0) led to
the best result (pIC50 of 4.53). The esters rac-19b, rac-19d
with a small or medium-sized bridge were equally suited to
address mGAT4. As the esters rac-19b, rac-19d, and rac-
19f displayed almost equal inhibitory potencies at mGAT1,
no effect of the bridge size on the biological activity at this
GAT subtype could be noticed. Finally, the structurally
related phenyl substituted esters rac-19h, rac-19k, and rac-
19m with a butyl spacer (n= 1) were compared among each
other to study the influence of the bridge size on the bio-
logical activity for these compounds. Ester rac-19k with a
medium-sized bridge (m= 1) demonstrated to be superior
as compared to esters rac-19h and rac-19m with regard to
inhibitory activities at mGAT1–mGAT3. Since at mGAT4
the inhibitory potency of esters rac-19h, rac-19k, and rac-
19m was decreasing with an increase in bridge size, the
ester rac-19h led with a pIC50 value of 4.89 to the best
result. However, by the above obtained results no general
correlation between the biological activity at a certain GAT
subtype and the bridge size (m) in the lipophilic domain of
the tested carboxylic acids rac-11a–m or their corre-
sponding esters rac-19a–m could be concluded.
Interestingly, all phenyl substituted nipecotic acid ester
derivatives, i.e., rac-19b, rac-19d, rac-19f, rac-19h, rac-
19k, and rac-19m exhibited higher inhibitory potencies at
mGAT1–mGAT4 than their corresponding carboxylic
acids. For the methyl-substituted nipecotic acid ester deri-
vatives no such universal effect was observed. The former
phenyl substituted nipecotic acid derivatives showed rather
equal inhibitory potencies at all four GAT subtypes (Table
4, see entries for compounds rac-19b, rac-19d, rac-19k,
and rac-19m), but also a weak subtype selectivity for
mGAT3 and for mGAT4 was achieved with ester rac-19f
(pIC50 value of 4.97 at mGAT3; Table 4, entry 11) and ester
rac-19h (pIC50 value of 4.89 at mGAT4; Table 4, entry 15),
respectively. These esters, rac-19f and rac-19h, represent
the first subtype selective GAT inhibitors carrying a cage
unit in the lipophilic domain.
Still to be mentioned is the fact, that the binding affinities
at mGAT1 determined in binding assays often do not cor-
relate with the inhibitory potencies from mGAT1 uptake
assays. This phenomenon, the cause of which is still to be
clarified, can be seen for example in case of ester rac-19k.
This compound, rac-19k, exhibits a pIC50 value of 4.60 at
mGAT1 in the uptake assay, but a reduction of remaining
NO711 marker binding in the binding assay to 84% only (at
a test compound concentration of 100 µM).
Conclusion
Inspired by the drug Deramciclane (rac-9), a new class of
GABA uptake inhibitors with bulky and highly rigid tri-
cyclic subunits in the lipophilic domain delineated from
the 2-azabicyclo[2.2.2]octane scaffold by the presence of
an additional carbon bridge was developed. The poly-
cyclic subunits are connected via a plain hydrocarbon
spacer with the amino nitrogen of nipecotic acid or that of
the corresponding ethyl ester. For the synthesis of the new
compounds, nipecotic acid derivates with an N-alkyl
residue displaying a terminal aldehyde function, were
connected with symmetric tricyclic amines by reductive
amination. The tricyclic amines used were either gener-
ated in situ from tricyclic imines serving as precursors
directly before the reductive amination by the same
reducing agent or they were generated from the tricyclic
imines in a separate reaction step. The new GAT inhibi-
tors varied in regard to the spacer length, the size of one of
the bridges of the tricyclic skeleton of the lipophilic
domain and the substituents attached to the latter.
Whereas the nipecotic acid derived GAT inhibitors dis-
played only weak inhibitory potencies and binding affi-
nities at the four different GAT subtypes, all phenyl
substituted nipecotic acid ethyl ester derivatives exhibited
moderate biological activity at mGAT1–mGAT4. The
structure activity relationship of these GAT inhibitors
demonstrated the importance of the phenyl residues and
the ester function for the biological activity. Two of the
phenyl substituted nipecotic acid ethyl ester derivates,
rac-19f and rac-19h, being equipped with either a propyl
spacer and a C3-bridge (rac-19f) or a butyl spacer and a
methylene bridge (rac-19h), showed even moderate sub-
type selectivity at mGAT3 and mGAT4 respectively. As
demonstrated by the obtained results tricyclic cage
structures represent promising subunits for the construc-
tion of novel GAT inhibitors.
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